<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003264.pub3" GROUP_ID="RENAL" ID="373100100511032829" MERGED_FROM="" MODIFIED="2012-01-30 02:57:35 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="035" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2012-01-30 02:57:35 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Growth hormone for children with chronic kidney disease</TITLE>
<CONTACT MODIFIED="2012-01-30 02:57:35 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16110" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elisabeth</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hodson</LAST_NAME><EMAIL_1>Elisabeth.hodson@health.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-30 02:57:35 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16110" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elisabeth</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hodson</LAST_NAME><EMAIL_1>Elisabeth.hodson@health.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="9199" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Narelle</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Willis</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>narelle.willis@health.nsw.gov.au</EMAIL_1><URL>http://www.cochrane-renal.org</URL><ADDRESS><DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451485</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="4552" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1><EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>University of Sydney</ORGANISATION><ADDRESS_1>Edward Ford Building A27</ADDRESS_1><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-01-30 12:53:40 +1100" MODIFIED_BY="Narelle Willis">
<UP_TO_DATE>
<DATE DAY="29" MONTH="12" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="12" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="6" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-30 12:54:59 +1100" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2012-01-30 12:54:59 +1100" MODIFIED_BY="Narelle S Willis">
<DATE DAY="30" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>This review is no longer being updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-01-30 12:54:30 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-01-30 12:54:30 +1100" MODIFIED_BY="Narelle S Willis">
<DATE DAY="9" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>No change to conclusions</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-30 12:54:28 +1100" MODIFIED_BY="Narelle S Willis">
<DATE DAY="9" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>New studies added; flow chart added; summary of findings tables added; risk of bias assessment has replaced quality assessment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 17:57:35 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="1" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Small Grants Scheme of the Children's Hospital at Westmead</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Child Health Field Bursary</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Australian Kidney Foundation</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-03 08:43:00 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2012-01-01 15:29:11 +1100" MODIFIED_BY="[Empty name]">
<TITLE>There is some evidence that human growth hormone may help reduce growth problems in children with chronic kidney disease</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-01 15:29:11 +1100" MODIFIED_BY="[Empty name]">
<P>The kidneys filter blood. Children with chronic kidney disease (CKD) may progress to end-stage kidney failure and need their blood filtered by machine (dialysis) or they need a kidney transplant. CKD can stunt growth in children. Growth hormone (rhGH) has been used to help children grow to a more average height for their age but rhGH may have adverse effects including added risk of transplant rejection and high pressure in the brain. This review of 16 studies enrolling 809 children found that rhGH increased height in children with CKD by about 4 cm after 1 year and by a further 2 cm after 2 years of treatment compared with no treatment. The frequency of reported side effects of rhGH was generally similar to that of the control group.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-03 08:43:00 +1100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-01 12:35:47 +1100" MODIFIED_BY="[Empty name]">
<P>Growth retardation is a common complication of chronic kidney disease (CKD) in children and is of concern to families. Recombinant human growth hormone (rhGH) treatment has been used to help short children with CKD attain a height more in keeping with their age group. However there are concerns about the long-term benefits of rhGH in significantly improving adult height as well as concerns about potential adverse effects (deterioration in native kidney function, increased acute rejection in kidney transplant recipients, benign intracranial hypertension).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the benefits and harms of rhGH treatment in children with CKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-01-01 12:35:18 +1100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) were identified from the Cochrane Renal Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2011), MEDLINE (from 1966), EMBASE (from 1980), article reference lists and through contact with local and international experts in the field.</P>
<P>Date of last search: December 29, 2011<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-16 18:01:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>RCTs were included if they were carried out in children aged zero to 18 years, diagnosed with CKD, who were pre-dialysis, on dialysis or post-transplant; if they compared rhGH treatment with placebo/no treatment or two doses of rhGH treatments; and if they included height outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-02 21:19:23 +1100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed studies for risk of bias and extracted data from eligible studies. Data was pooled using a random effects model with calculation of mean difference (MD) for continuous outcomes with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-03 08:43:00 +1100" MODIFIED_BY="Narelle S Willis">
<P>Sixteen studies (enrolling 809 children) were identified. Risk of bias assessment indicated that study quality was poor or poorly reported with only four and five studies respectively reporting adequate allocation concealment or blinding of study participants and investigators. Treatment with rhGH (28 IU/m²/wk) compared with placebo or no specific therapy resulted in a significant increase in height standard deviation score (HSDS) at one year (8 studies, 391 children: MD 0.82, 95% CI 0.56 to 1.07), and a significant increase in height velocity at six months (2 studies, 27 children: MD 2.85 cm/6 mo, 95% CI 2.22 to 3.48) and one year (7 studies, 287 children: MD 3.88 cm/y, 95% CI 3.32 to 4.44). Height velocity, though reduced, remained significantly greater than untreated children during the second year of therapy (1 study, 82 children: MD 2.30 cm/y, 95% CI 1.39 to 3.21). Compared to the 14 IU/m²/wk group, there was a 1.18 cm/y increase in height velocity in the 28 IU/m²/wk group (3 studies, 150 children: 1.18 cm/y, 95% CI 0.52 to 1.84) . The frequency of reported side effects of rhGH was generally similar to that of the control group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-02 20:49:42 +1100" MODIFIED_BY="[Empty name]">
<P>One year of 28 IU/m²/wk rhGH in children with CKD resulted in a 3.88 cm increase in height velocity above that of untreated patients. Studies were too short to determine if continuing treatment resulted in an increase in final adult height.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-01-01 17:50:25 +1100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-01-01 14:27:55 +1100" MODIFIED_BY="[Empty name]">
<P>Chronic kidney disease (CKD) is an uncommon but important condition. As defined by the need for dialysis or kidney transplant (stage 5 CKD; <LINK REF="REF-K_x002f_DOQI-2002" TYPE="REFERENCE">K/DOQI 2002</LINK>), 32/1,000,000 children under the age of 15 have CKD (<LINK REF="REF-Disney-1999" TYPE="REFERENCE">Disney 1999</LINK>). Many more children have less advanced CKD (stage 3 CKD with glomerular filtration rate (GFR) 30 to 59 mL/min/1.73 m² and stage 4 CKD with GFR 15 to 29 mL/min/1.73 m²). The frequency of this problem is unclear. Growth retardation, one of the complications of CKD, is of concern to families in over 90% of children with stage 5 CKD (<LINK REF="REF-Reynolds-1995" TYPE="REFERENCE">Reynolds 1995</LINK>). Approximately 60% of boys and 41% of girls who started renal replacement therapy before the age of 15 years attain a final adult height more than two standard deviations (12 cm) below the mean for healthy adults (<LINK REF="REF-Rizzoni-1985" TYPE="REFERENCE">Rizzoni 1985</LINK>). Impairment of growth can begin when the GFR falls to 50% of normal, and becomes an increasing problem once the GFR falls below 25% (<LINK REF="REF-T_x00f6_nshoff-1995" TYPE="REFERENCE">Tönshoff 1995</LINK>).</P>
<P>Over the past 20 years, recombinant human growth hormone (rhGH) treatment has been used to help short children with CKD attain an adult height more in keeping with their age group (<LINK REF="REF-Berard-2008" TYPE="REFERENCE">Berard 2008</LINK>; <LINK REF="REF-Fine-1995a" TYPE="REFERENCE">Fine 1995a</LINK>; <LINK REF="REF-Haffner-2000" TYPE="REFERENCE">Haffner 2000</LINK>). However, there have been concerns that rhGH may have an adverse effect on the preservation of native kidney function, predispose to acute rejection in kidney transplant recipients, and cause benign intracranial hypertension (BIH) and slipped capital femoral epiphysis (<LINK REF="REF-Clayton-2000" TYPE="REFERENCE">Clayton 2000</LINK>).</P>
<P>Although several studies of rhGH treatment in children with CKD have been undertaken, uncertainty exists on the magnitude of benefits and side effects of the treatment (<LINK REF="REF-Fine-1995a" TYPE="REFERENCE">Fine 1995a</LINK>). A systematic review of rhGH treatment was undertaken to evaluate growth outcomes to establish the effect of treatment over time. We sought to establish if the growth outcomes remained linear over time or if there was a waning effect of the treatment. Secondly, we examined the effect of varying doses of the treatment. Thirdly, we attempted to explore the effect of the following factors on treatment: age, sex, pubertal status and the stage of CKD (pre-dialysis, on dialysis, post-transplant). Finally, the study evaluated potential side effects of rhGH treatment.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-01-01 12:38:14 +1100" MODIFIED_BY="[Empty name]">
<P>This review aims to evaluate the benefits and harms of rhGH treatment in children aged zero to 18 years, diagnosed with CKD who are treated conservatively (CKD stages 3, 4), treated with dialysis (CKD 5D) or treated with a kidney transplant (CKD 5).</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-01-01 17:50:25 +1100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-01-01 12:43:43 +1100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) that compared rhGH treatment with placebo/no treatment or that compared two doses of rhGH.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-01-01 12:39:13 +1100" MODIFIED_BY="Narelle S Willis">
<P>Children between the ages of zero to 18 years, diagnosed with CKD who are pre-dialysis (preD), on dialysis (Dial) or post-transplant (TP).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>rhGH treatment compared with placebo/no treatment or comparison of two doses of rhGH treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-01-01 12:43:43 +1100" MODIFIED_BY="[Empty name]">
<P>The growth outcomes were collected in the form of standard deviation score (SDS). As such, an individual's height SDS (HSDS) was calculated as follows:</P>
<UL>
<LI>(actual height - mean height for age)/standard deviation at that age</LI>
</UL>
<P>Normal children have a height that ranges between -2 and +2 SDS. If a change in HSDS is negative, it implies growth failure and if positive, catch-up growth.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-01-01 12:40:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>The primary outcome measures were the end of treatment HSDS or change in HSDS from treatment onset to completion and the end of treatment height velocity or change in height velocity.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-01-01 12:40:08 +1100" MODIFIED_BY="Narelle S Willis">
<P>Secondary outcomes sought included final or change in HSDS and height velocity during puberty, final or change in height velocity SDS, final height, change in bone age, quality of life, and adverse effects of rhGH treatment (kidney function, rejection episodes, benign intracranial pressure and any other possible side effects reported).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-01-01 17:50:25 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Initial search</HEADING>
<P>A systematic and comprehensive literature search was carried out to identify eligible RCTs. Two authors independently searched the following electronic databases without language restriction, using the optimally sensitive search strategies developed for identification of RCTs (<LINK REF="REF-Dickersin-1995" TYPE="REFERENCE">Dickersin 1995</LINK>; <LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>). (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> - <I>Electronic search strategies</I>).</P>
<OL>
<LI>The Cochrane Controlled Trials Register (Issue 1, 2000)</LI>
<LI>MEDLINE (1966-April 2000)</LI>
<LI>EMBASE (1980-April 2000)</LI>
<LI>Additional studies were located through article reference lists and through contact with local and international experts in the field.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Review updates</HEADING>
<UL>
<LI>First update: The Cochrane Renal Group's specialised register (July 2005) and The Cochrane Central Register of Controlled Trials (CENTRAL, in <I>The Cochrane Library</I> Issue 3, 2005) were searched.</LI>
<LI>Second update: The Cochrane Renal Group's specialised register was searched up to December 29, 2011 for the second update. CENTRAL and the Renal Group's specialised register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective. Please refer to The Cochrane Renal Review Group's Module in <I>The Cochrane Library</I> for the complete list of nephrology conference proceedings searched (<A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>).</LI>
</UL>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-12-29 15:53:55 +1100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-12-29 14:34:37 +1100" MODIFIED_BY="[Empty name]">
<P>At least two people independently screened titles and abstracts of studies identified through the searches and selected studies that met the inclusion criteria. This process favoured over-selection to avoid losing relevant studies. In the event of uncertainty or no abstract available, the full article was obtained. Any disagreement on study selection was resolved through discussion and consultation with a third author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-06-19 00:47:32 +1000" MODIFIED_BY="[Empty name]">
<P>Data extraction and assessment of the risk of bias were carried out independently by at least two people using standard data extraction forms. Studies reported in non-English language journals were translated before assessment. Information was collected on participant characteristics (number, age, sex, pubertal stage, stage of CKD, comorbidities), intervention (type of growth hormone, dose, duration, co-interventions) and primary and secondary outcome measures. Authors were contacted to obtain any missing data, as well as raw data when necessary. Any discrepancies in data extraction were discussed with another author. In the case where the results of a study were published more than once, or the results discussed in a number of publications, the most complete data were obtained using all sources and included in the analysis only once.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-12-29 15:23:24 +1100" MODIFIED_BY="[Empty name]">
<P>The following items were assessed using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-11-02 20:49:59 +1100" MODIFIED_BY="[Empty name]">
<P>Difference in means was calculated for continuous outcomes of individual studies to estimate the size of the intervention effects. Overall treatment effects (mean difference (MD)) were computed using a random effects model which takes into account between study variability as well as within study variability.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-11-02 20:50:06 +1100" MODIFIED_BY="[Empty name]">
<P>In the case of cross-over studies, data from the first half of the study was extracted where these were reported separately and used in the analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-12-29 15:23:39 +1100" MODIFIED_BY="[Empty name]">
<P>We contacted the triallists to request missing patient data due to loss to follow-up and exclusion from study analyses in an effort to carry out intention-to-treat analyses. Where the missing dichotomous or continuous data were few and unlikely to affect the overall results, we analysed the available data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-12-29 15:53:55 +1100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was analysed using Cochran's Q statistic (<LINK REF="REF-Pettiti-1994" TYPE="REFERENCE">Pettiti 1994</LINK>) with an alpha of 0.05 used for statistical significance and quantified with the I² statistic. I² values of 30% to 60%, 50% to 90% and 75% to 100% correspond to low, substantial and considerable levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-07-23 16:05:32 +1000" MODIFIED_BY="[Empty name]">
<P>The search strategy included searching major databases and conference proceedings without language restriction in an attempt to reduce publication bias related to failure of authors to publish negative results or inability to publish negative results in journals indexed in major databases. Where multiple publications of the same study were identified, data were included from the most recent publication and preferably the definitive publication. However all publications were reviewed to identify outcomes not reported in the index publication in an attempt to reduce outcome reporting bias. There were insufficient studies to assess for publication bias using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-06-19 00:44:32 +1000" MODIFIED_BY="[Empty name]">
<P>Data were pooled using the random-effects model for continuous data.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-06-19 00:50:35 +1000" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was planned to explore the effects of age, sex, pubertal status, and stage of CKD on rhGH treatment. There were sufficient data to investigate pubertal status and stage of CKD.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-12-29 15:24:39 +1100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were performed to test decisions where inclusion of a study, with a higher MD in HSDS, might have altered the results of the meta-analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-01-01 17:43:43 +1100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-01-01 17:43:43 +1100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-01-01 17:43:43 +1100" MODIFIED_BY="[Empty name]">
<P>The flow chart of study inclusion for this review is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>The original search identified 337 titles and abstracts, of which 297 were excluded. The excluded studies were either clearly not clinical studies or rhGH treatment was only used in children with idiopathic short stature. Full assessment of the remaining 40 papers identified 12 articles that addressed the use of rhGH treatment in children with CKD and provided data on clinically important outcomes of which two papers reported data on a subset of patients within other studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>). Thus 10 studies enrolling 620 children were evaluated (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>). From <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>, only data on transplant patients were included since data on the same dialysis (<LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>) and predialysis patients (<LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) were taken from the Kitagawa trial.</P>
<P>A further search in July 2005 of The Cochrane Central Register of Controlled Trials (CENTRAL, in <I>The Cochrane Library,</I> Issue 3 2005), the Cochrane Renal Group's specialised trials register, MEDLINE and EMBASE identified 23 further potentially relevant articles. Of these 23 articles, five were considered to be newly identified studies (<LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Ghio-2002-_x0028_TP_x0029_" TYPE="STUDY">Ghio 2002 (TP)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>) and four were abstracts of previously included studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>). In addition one abstract provided extra information on kidney function for <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK> and one article described a study of body proportions measured during two previously included studies (<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>). Thus an additional five studies involving 150 children were included.</P>
<P>In December 2011 the Cochrane Renal Group's specialised trials register was searched and identified 13 articles of which two, after full text assessment, were new RCTs (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) and nine were publications related to previously included studies. On re-assessing risk of bias of the existing included studies, <LINK REF="STD-Ghio-2002-_x0028_TP_x0029_" TYPE="STUDY">Ghio 2002 (TP)</LINK> was excluded as the study was considered not to be randomised. Therefore the review now contains 16 studies enrolling 809 children.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-01-01 13:17:38 +1100" MODIFIED_BY="[Empty name]">
<P>Fourteen of the 16 studies used a parallel design while the other two were cross-over studies. The studies varied in duration (six months to 2.5 years) and included children from the USA, Europe and Japan. At enrolment, most children were prepubertal or early pubertal, with one study including late pubertal children (<LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>). Three studies included only pre-dialysis patients (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>); one study included only dialysis patients (<LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>); five studies included pre-dialysis and dialysis patients (<LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK> ) but the two groups could only be separated in one study (<LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) and this study was treated as two studies of dialysis and predialysis patients respectively. The remaining eight studies enrolled children with kidney transplants (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>). <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK> and <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK> was treated as two studies as data on pubertal and prepubertal children were reported separately. Three studies compared rhGH (28 IU/m²/wk) with placebo (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>) and seven studies compared rhGH (28 IU/m²/wk) with no treatment (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>). The remaining six studies compared two different doses of rhGH: five studies compared 28 IU/m²/wk with 14 IU/m²/wk (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) and one study compared 56 IU/m²/wk with 28 IU/m²/wk (<LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>). The type of rhGH administered in the studies included Norditropin®, Nutropin®, Genotropin® and Genotonorm®.</P>
<P>The primary publication of the <LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK> study included 203 children of whom efficacy (change in HSDS and height velocity) was evaluated in 125 children (66 treated and 59 untreated) and safety (GFR, acute rejection, other adverse effects) was evaluated in 180 children. The data on growth was reported separately for prepubertal children, children entering puberty and pubertal children and not for the entire group. Therefore for the analyses of growth overall (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), data from the 1998 publication by Guest et al, of 85 French children (41 treated, 44 treated) are included while the data from <LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK> are separately reported in <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> and <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-11-02 20:54:36 +1100" MODIFIED_BY="[Empty name]">
<P>Three studies (<LINK REF="STD-Ghio-2002-_x0028_TP_x0029_" TYPE="STUDY">Ghio 2002 (TP)</LINK>; <LINK REF="STD-Jedrzejowski-2002" TYPE="STUDY">Jedrzejowski 2002</LINK>; <LINK REF="STD-Laine-1995" TYPE="STUDY">Laine 1995</LINK>) were excluded as they were not RCTs.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-01-01 17:11:54 +1100" MODIFIED_BY="[Empty name]">
<P>Risk of bias is reported for each study in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2012-01-01 12:50:53 +1100" MODIFIED_BY="[Empty name]">
<P>No study provided information on sequence generation. Adequate allocation concealment was reported in four studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-12-29 15:57:02 +1100" MODIFIED_BY="[Empty name]">
<P>There was considered to be a low risk of performance bias in five studies (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>). There was considered to be a high risk of performance bias in 11 studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) because studies were not blinded and the outcome could potentially be biased by knowledge of treatment groups.</P>
<P>In four double-blind studies, the same investigator measured each child throughout the study (<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>). However it was unclear whether this investigator was blinded to the treatment groups. Thus no study reported on whether outcome assessors were blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-12-29 15:57:02 +1100" MODIFIED_BY="[Empty name]">
<P>Eight studies were considered to be at low risk of bias (<LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) while five were considered to be at high risk (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>). In the remaining three studies it was unclear whether the number of children excluded from analysis or lost to follow-up would influence the study results (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-12-29 15:35:41 +1100" MODIFIED_BY="[Empty name]">
<P>Whether there was selective reporting of outcomes was unclear in six studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>). In the remaining 11 studies it was considered that all outcomes had been reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-12-29 15:35:41 +1100" MODIFIED_BY="[Empty name]">
<P>Two studies did not report on sponsorship (<LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>). The other 14 studies were funded by pharmaceutical companies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-01-01 15:30:37 +1100" MODIFIED_BY="[Empty name]">
<P>Sixteen studies enrolling 809 children were evaluated. There were no substantial differences between summary estimates calculated using random and fixed effects models and only results of the random effects models are reported here.</P>
<SUBSECTION>
<HEADING LEVEL="3">Change in height standard deviation score</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">rhGH versus placebo/no treatment</HEADING>
<P>The effect of rhGH compared to placebo/no specific treatment on HSDS was reported in eight studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>). Children treated with rhGH for one year showed an increase in HSDS of 0.82 compared with placebo/no specific treatment (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (8 studies, 331 children): MD 0.82, 95% CI 0.56 to 1.07). In a child of age 10, an MD of 0.82 approximates to about 5 cm of growth in one year.</P>
<P>Although there was some heterogeneity (I² = 44%) in the degree of benefit of rhGH compared with placebo/no specific treatment, all studies reported an improvement in HSDS with therapy. In subgroup analysis (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) heterogeneity in the efficacy of rhGH on HSDS was not explained by differences between studies involving transplant patients and those with CKD or end-stage kidney disease (ESKD). Heterogeneity was reduced in sensitivity analyses by removal of the studies by <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK> and <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>, which showed larger differences in HSDS between rhGH treated and non-treated children. There was no obvious variation demonstrated in the change of HSDS with pubertal status in one study (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>In one study (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>) data were available for two years of treatment. Most of this growth acceleration occurred in the first year of rhGH therapy (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.1). Treatment in the second year resulted in a small and not significant increase in HSDS (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.2 (1 study; 82 children): MD 0.37, 95% CI -0.10 to 0.84). However treatment for two years with rhGH resulted in a persisting significant difference in HSDS between rhGH treated children and untreated children (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.3 (1 study, 82 children): MD 1.36, 95% CI 0.86 to 1.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">rhGH: 28 IU/m²/wk versus 14 IU/m²/wk</HEADING>
<P>Three studies (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) compared 28 IU/m²/wk with 14 IU/m²/wk and reported data on HSDS. There was no significant difference in the change in HSDS between baseline and one year (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1 (3 studies, 145 children): MD 0.20, 95% CI -0.09 to 0.48). <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK> and <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK> showed no difference in HSDS between the two groups over six months (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2 (1 study, 40 children): MD 0.20, 95% CI -0.33 to 0.73) and between six months and one year (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.3 (1 study, 40 children): MD 0.12, 95% CI -0.43 to 0.68). There was no obvious difference in the change in HSDS with rhGH according to the stages of CKD in one study (<LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">rhGH: 28 IU/m²/wk versus 56 IU/m²/wk</HEADING>
<P>One study (<LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>) compared 28 IU/m²/wk with 56 IU/m²/wk and showed no difference between groups in the change in HSDS at one year of treatment (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (1 study, 16 children): MD 0.30, 95% CI -1.00 to 1.60).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Change in height velocity</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">rhGH versus placebo/no treatment</HEADING>
<P>Nine studies compared rhGH with placebo/no treatment and presented data on height velocity (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>). Two studies (<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>) reported six month outcome data and showed an increase in height velocity of 2.85 cm over six months (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (2 studies, 27 children): MD 2.85 cm/6 mo, 95% CI 2.22 to 3.48). Seven studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) showed an increase in height velocity over one year of 3.88 cm/y (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (7 studies, 288 children): MD 3.88, 95% CI 3.32 to 4.44).</P>
<P>
<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK> separately reported results for the second year of the study. Growth velocity fell from 4.2 cm/y in the first year <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.4) to 2.3 cm/y in the second year of rhGH treatment (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.5) and there was a greater decrease in height velocity in the rhGH-treated group relative to the untreated group (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.6 (1 study, 82 children): MD -1.90 cm/y, 95% CI -3.04 to -0.76). However height velocity in the rhGH treated group still remained significantly higher than in the untreated group (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.5 (1 study, 82 children): MD 2.30 cm/y, 95% CI 1.39 to 3.21) during the second year of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">rhGH: 28 IU/m²/wk versus 14 IU/m²/wk</HEADING>
<P>Four studies (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) comparing 28 IU/m²/wk with 14 IU/m²/wk of rhGH reported height velocity outcomes. Three studies showed a significant increase in height velocity with 28 IU /m²/wk compared with 14 IU /m²/wk for one year (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.3 (3 studies, 150 children): MD 1.18 cm/y, 95% CI 0.52 to 1.84). One study (<LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>) showed an increase in height velocity to six months with 28 IU /m²/wk compared with 14 IU /m²/wk (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.1 (1 study, 80 children): MD 1.96 cm/6 mo, 95% CI 0.86 to 3.05), which waned during the second six months of intervention (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>.2 (1 study, 80 children): MD -0.53 cm/6 mo, 95% CI -1.65 to 0.59). Another study (<LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>) reported a 2.7 cm/y (14 IU/m²/wk) and a 2.6 cm/y (28 IU/m²/wk) increase in height velocity but there was no statistical difference between treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">rhGH: 56 IU/m²/wk versus 28 IU/m²/wk</HEADING>
<P>
<LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK> compared 56 IU/m²/wk with 28 IU/m²/wk of rhGH and showed no significant difference in mean height velocity (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (1 study, 16 children): MD 1.10 cm/y, 95% CI -1.30 to 3.50) during one year of treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Change in height velocity standard deviation score</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">rhGH versus placebo/no treatment</HEADING>
<P>Three studies comparing growth hormone treatment with placebo/no treatment reported data on height velocity SDS. Two studies (<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>) reported an increase in height velocity SDS over six months duration (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.1 (2 studies, 27 children): MD 7.80, 95% CI 6.09 to 9.51) and one study (<LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>) reported an increase over one year (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.2 (1 study; 22 children): MD 6.14, 95% CI 3.41 to 8.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">rhGH: 28 IU/m²/wk versus 14 IU/m²/wk</HEADING>
<P>Three studies reported data on height velocity SDS. Height velocity SDS at one year was significantly higher in 28 IU/m²/wk compared with 14 IU/m²/wk of rhGH (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.1 (2 studies, 106 children): MD 1.48, 95% CI 0.03 to 2.93). Height velocity SDS was significantly increased with 28 IU/m²/wk at six months (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.2 (2 studies, 103 children): MD 2.05, 95% CI 0.82 to 3.28) but not between six months and one year (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.3 (1 study; 40 children): MD -0.65, 95% CI -2.09 to 0.80).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Change in body proportions</HEADING>
<P>Two studies (<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>;<B> </B>
<LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>) provided additional information on body proportions (sitting height, arm span, lengths of body segments). Results were provided as changes in SDS but no standard deviations or confidence intervals were provided so graphical analysis was not possible. Body proportions in children with CKD or ESKD did not differ from those seen in normal children. During rhGH therapy, body segments growth remained appropriate indicating that growth hormone did not influence body proportions during catch up growth.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Change in bone age</HEADING>
<P>Seven studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) all comparing rhGH treatment with placebo/no treatment, presented data on bone age. There was no significant difference in the change in bone age between the two groups over six months (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.1 (2 studies, 27 children): MD -0.15, 95% CI -1.77 to 1.48), one year (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.2 (4 studies, 202 children): MD 0.02, 95% CI -0.27 to 0.31 or between one and two years of treatment (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.3 (1 study, 40 children): MD 0.40, 95% CI -0.99 to 1.79).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Kidney function</HEADING>
<P>Nine studies comparing rhGH therapy with placebo or no treatment provided some information on kidney function (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>); the tenth study involved only dialysis patients (<LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>). All reported that kidney function did not differ between treated and control groups. Similarly in the six studies comparing different doses of rhGH, no differences in kidney function were identified among pre-dialysis or transplant patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lipids</HEADING>
<P>
<LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK> reported data on lipids and found no difference in cholesterol, triglycerides, apolipoproteins (Apo-A<SUB>1</SUB>, Apo-B).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Glucose tolerance</HEADING>
<P>Seven studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>; <LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>; <LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>) reported data on fasting blood glucose, HbA<SUB>1C</SUB> and insulin levels. Fasting blood glucose and HbA<SUB>1C </SUB>remained generally within the normal range in both treatment groups but insulin levels were higher in rhGH treated patients. Individual patients developed glucose intolerance or frank diabetes mellitus (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> - <I>Reported adverse effects). </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Acute rejection</HEADING>
<P>Information on the incidence of acute rejection in kidney transplant recipients was reported in seven studies (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>; <LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>; <LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>). <LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK> reported that acute rejection episodes were more frequent in rhGH treated patients and that episodes were more frequent overall among recipients with more than one previous episode of acute rejection. The other studies noted no significant increase in rejection episodes in rhGH treated patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Benign intracranial hypertension</HEADING>
<P>BIH was reported in one child treated with rhGH (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>) and one patient in the control group (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>). The remaining studies did not provide any information on BIH.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Reporting of adverse effects was generally scant. A number of papers reported adverse effects collectively without specifying the treatment group to which the subjects belonged. Reported side effects included asthma/wheezing, acute rejection in transplantation, deterioration in kidney function, raised fasting glucose, papilledema, glucose intolerance, granuloma formation, lymph node swelling, claudication, hypertension and worsening of pre-existing idiopathic scoliosis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> - <I>Reported adverse effects</I>). Only one study (<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>) demonstrated a significant increase in adverse events in the rhGH group relative to the control group (using composite end-point data). A pooled estimate of rhGH-related adverse effects was not possible because of insufficient data in the primary studies.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-01-01 17:30:41 +1100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-01-01 14:27:56 +1100" MODIFIED_BY="[Empty name]">
<P>rhGH is effective in improving the growth of children with CKD during the first year of administration, with increases in all height indices. In children treated with rhGH, HSDS increases by 0.82 SDS, height velocity increases by 3.88 cm/y and height velocity SDS increases by 6 SDS above that of non-treated controls. It is likely that such growth will not be lost in later life and represents a long-term increase in growth potential. Within these short-term randomised studies, no variation in response to rhGH could be demonstrated between pre-pubertal and pubertal patients and between stage 3 and 4 CKD and stage 5 CKD treated by dialysis or by transplantation.</P>
<P>Available RCT data suggest that children with CKD should be treated with 28 IU/m²/wk of rhGH. Compared with a dose of 14 IU/m²/wk, the larger dose increases height by about 1.5 cm/y over one year but increasing the dose to 56 IU/m²/wk did not result in a statistically significant improvement in growth indices. However, these conclusions are based on only 18 patients. Using the 95% CI to quantify the uncertainty about the effect of the higher dose, relative to those patients given 28 IU/m²/wk, children given 56 IU/m²/wk may grow more than 3.43 cm/y taller in the first year or be 1.23 cm/y shorter.</P>
<P>Across all growth outcomes, there was a consistent pattern of waning effect with longer duration of treatment. This time-dependency could not be formally tested due to insufficient data points, however, observation of the study data is strongly suggestive of this relationship. For example, the differences in height velocity between the treated and untreated children were 2.85 cm/y (95% CI 2.22 to 3.48) for the first six months, 3.88 cm/y (95% CI 3.32 to 4.44) for the first year<B> </B>and -1.90 cm/y (95% CI -3.04 to -0.76)<B> </B>for the second year. The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry found that HSDS improved by +0.5 SD following five years of rhGH therapy (<LINK REF="REF-Fine-2010" TYPE="REFERENCE">Fine 2010</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-01-01 17:30:41 +1100" MODIFIED_BY="[Empty name]">
<P>The Identified studies only examined growth rates for a maximum of two years. No differences in efficacy were identified between pubertal and pre pubertal children or between different stages of CKD. However longer term cohort studies have demonstrated that response to rhGH therapy is better in prepubertal compared with pubertal children (<LINK REF="REF-Haffner-2000" TYPE="REFERENCE">Haffner 2000</LINK>) and in stage 3 and 4 CKD compared with stage 5 CKD treated by dialysis or transplant (<LINK REF="REF-Berard-2008" TYPE="REFERENCE">Berard 2008</LINK>; <LINK REF="REF-W_x00fc_hl-1996" TYPE="REFERENCE">Wühl 1996</LINK>).</P>
<P>The most important height outcome is final or adult height. No RCTs have been published with final adult height as an outcome. However published study data do provide some indirect support that rhGH improves final adult height in children. During two years of rhGH treatment, there was no evidence that children grew less than their non-rhGH treated counterparts, even during the second year. There was no evidence that rhGH advanced the pubertal growth spurt, speeding up the normal growth process, or that it advanced bone age in the six studies in which this was evaluated. Data from children treated with rhGH, and followed till they achieved final adult height, indicate that treated children had sustained catch up growth whereas untreated matched children had progressive growth failure (<LINK REF="REF-Haffner-2000" TYPE="REFERENCE">Haffner 2000</LINK>). Final adult height was 165 cm in boys and 156 cm in girls in treated children. The final adult height was -1.6 ± 1.2 SDS in treated children and -2.1 ± 1.2 SDS in untreated children. Improved final height in rhGH treated children has also been reported from the NAPRTCS registry (<LINK REF="REF-Fine-2005" TYPE="REFERENCE">Fine 2005</LINK>) and by the French Society of Pediatric Nephrology (<LINK REF="REF-Berard-2008" TYPE="REFERENCE">Berard 2008</LINK>) in children treated with rhGH.</P>
<P>Few adverse events were reported but the studies were underpowered to detect clinically important differences in adverse event rates. Several studies reported that adverse effects were minimal or did not report on adverse effects at all. In controlled studies for other indications and in observational studies of rhGH in children with or without CKD, adverse events (usually minor) are reported at a frequency of about 5/100 patient-years (<LINK REF="REF-Cowell-1995" TYPE="REFERENCE">Cowell 1995</LINK>; <LINK REF="REF-Wilton-1999" TYPE="REFERENCE">Wilton 1999</LINK>). BIH has been reported more commonly in rhGH treated patients than in the general population. Among different rhGH treated populations, BIH is most common in children with CKD and in children with Turner's Syndrome (<LINK REF="REF-Reeves-2002" TYPE="REFERENCE">Reeves 2002</LINK>). Acute rejection episodes were seen more commonly in rhGH treated patients in one study (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>). However subsequent assessment demonstrated no consistent relationship between rhGH therapy and acute rejection in transplant recipients.</P>
<P>The benefits of rhGH on growth need to be balanced with the difficulty of adhering to a daily subcutaneous injection regimen. However no study addressed this outcome. In a case series of children with CKD treated with rhGH for two years, children who responded to rhGH reported they would choose treatment again, and those who did not respond generally reported they would not choose treatment again (<LINK REF="REF-Postlethwaite-1998" TYPE="REFERENCE">Postlethwaite 1998</LINK>). These data suggest that treatment response overrides concerns about injections.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-01-01 14:23:21 +1100" MODIFIED_BY="[Empty name]">
<P>Sixteen RCTs were included in this review. Seven studies included only kidney transplant recipients, four studies included only predialysis patients while the remaining studies included both pre-dialysis and dialysis patients. Risk of bias assessment indicated that the methodological quality of the studies was generally poor with no study reporting the method of sequence generation and only four studies reporting adequate allocation concealment. Five studies were considered at low risk of performance bias as the control group received placebo injections. Although a single investigator undertook all the measurements in four studies, the risk of detection bias in these studies remained unclear as it was not clear whether the investigator was blinded to treatment groups. Studies without adequate allocation or blinding are considered to be at increased risk of bias (<LINK REF="REF-Moyer-1998" TYPE="REFERENCE">Moyer 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Eight and 12 studies respectively were considered at low risk of attrition bias or selective reporting. Fourteen studies reported pharmaceutical sponsorship.</P>
<P>The quality of evidence for the increase in HSDS and height velocity with rhGH compared with placebo/no specific therapy after one year of therapy was considered to be moderate, while the quality of evidence for the increase in height velocity after six months and the increase in height velocity SDS after one year was considered to be low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The quality of evidence for the change in HSDS and height velocity after one year with rhGH 28 IU/m²/wk compared with 14 IU/m²/wk was considered to be moderate while that for height velocity SDS was considered to be low (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-01-01 14:24:53 +1100" MODIFIED_BY="[Empty name]">
<P>This review identified 16 studies. Of these two were available in abstract form only (<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>; <LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>) and three other studies were available in only limited reports (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>; <LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>. Incomplete reporting of studies may result in inaccurate information being included in this systematic review. In particular the European multicentre study (<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>) enrolled 203 children while the preliminary publication provided growth data only on 125 children and these data were related to pubertal status (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The only other publication identified from this study provided data on a subset of 85 French children and data from this subset is included in the overall analysis of HSDS (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). It is possible that this subset of patients was not fully representative of the results seen in the larger group of children since the MD in HSDS was 0.3 SDS in the French children compared with MD of 0.5 to 0.7 SDS in the larger group of children (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>The literature search was run several times up to December 2011 making it unlikely that any studies have been missed. Only two additional studies were identified since the last update of this review. Of these was a recent study while <LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK> was a conference abstract from 1996 identified by handsearching since the last update of this review. Of study reports in the Cochrane Renal Group's specialised register 40% have been identified by handsearching of conference proceedings. It remains possible that further studies examining rhGH therapy in children with CKD will be identified as conference proceedings from different congresses are searched.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-01-01 14:25:16 +1100" MODIFIED_BY="[Empty name]">
<P>The findings of increased HSDS and height velocity with short-term rhGH therapy in the RCTs included in this review are in keeping with longer duration non-randomised studies with concurrent or historical control groups (<LINK REF="REF-Berard-2008" TYPE="REFERENCE">Berard 2008</LINK>; <LINK REF="REF-Haffner-2000" TYPE="REFERENCE">Haffner 2000</LINK>) and with the NAPRTCS registry data (<LINK REF="REF-Fine-2005" TYPE="REFERENCE">Fine 2005</LINK>; <LINK REF="REF-Fine-2010" TYPE="REFERENCE">Fine 2010</LINK>). In larger studies and registry data, response to rhGH is greater in younger children and in children treated conservatively. This could not be demonstrated among the included studies but total patient numbers included in the studies were small. This review suggested that response to rhGH is attenuated in the second year of therapy and this has been confirmed in longer term studies (<LINK REF="REF-Fine-2005" TYPE="REFERENCE">Fine 2005</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-01-01 14:29:24 +1100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-01-01 14:25:45 +1100" MODIFIED_BY="[Empty name]">
<P>Based upon existing RCT data, one year of 28 IU/m²/wk rhGH in children with CKD, regardless of their pubertal and treatment status (pre-dialysis, dialysis, post-transplant), results in an average height increase of 3.88 cm/y. Data from cohort studies suggest that rhGH<B> </B>results in an increase in final adult height and that the response in pre-pubertal children and/or stage 3 or 4 CKD exceeds that in pubertal and/or stage 5 CKD. Side effects of rhGH are uncommon.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-01-01 14:29:24 +1100" MODIFIED_BY="[Empty name]">
<P>Available studies are few, are of short duration, and underpowered to detect differences in treatment effects across sub-groups of patients based upon plausible effect modifiers including the duration of treatment, age, pubertal status and stage of CKD. Although the studies did have some heterogeneity of children, the magnitude of treatment effect could not be related to age, pubertal status or stage of CKD. Longer term cohort studies have documented greater responses to rhGH in pre pubertal children not on dialysis. However rhGH is now well established as a therapy for children with CKD and growth retardation though its use varies widely throughout the world. Therefore further RCTs are unlikely to be performed as withholding rhGH from short children would now not be considered appropriate. In addition, dose regimens are now standardised so that studies comparing different dose regimens would also not be considered necessary.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-01 17:12:01 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>This project was supported by the Australian Kidney Foundation, the Small Grants Scheme of the Children's Hospital at Westmead and the Cochrane Child Health Field Bursary.</LI>
<LI>The authors would like to thank:</LI>
<UL>
<LI>Dushyanthi Vimalachandra, Christopher Cowell and John Knight who all contributed to the design, quality assessment, data collection, entry, analysis, interpretation and the writing of the first (<LINK REF="REF-Vimalachandra-2001b" TYPE="REFERENCE">Vimalachandra 2001b</LINK>) and second versions (<LINK REF="REF-Vimalachandra-2006" TYPE="REFERENCE">Vimalachandra 2006</LINK>) of this review.</LI>
<LI>Professor R Fine, Dr I Salusky, Dr L Rees and Ms Dechant for information on unpublished studies and for additional information on published studies and Dr M Craig for assistance with data conversion.</LI>
<LI>Mohit Tolani, Brendan Nguyen and Dr Richard McGee for help with risk of bias assessment and Mohit Tolani for developing <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</LI>
<LI>The referees for their comments and feedback during the preparation of this review.</LI>
</UL>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-12-29 14:43:20 +1100" MODIFIED_BY="Narelle S Willis">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-08-25 14:14:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>EH and NW screened titles and abstracts of new searchs, independently extracted data and updated the review in 2006 and 2011.</LI>
<LI>JC resolved any disagreement through discussion and consultation.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-12-29 14:36:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Risk of bias assessment tool has replaced quality assessment checklist.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-12-29 16:05:30 +1100" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2011-12-29 16:05:30 +1100" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2011-12-29 16:04:38 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Broyer-1996-_x0028_TP_x0029_" MODIFIED="2011-11-16 21:55:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Broyer 1996 (TP)" YEAR="1996">
<REFERENCE MODIFIED="2011-08-29 15:02:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broyer M, Guest G, Crosnier H, Berard E, on behalf of the French Society for Pediatric Nephrology</AU>
<TI>A multicentric open randomized controlled study of rhGH therapy in short children after kidney transplantation [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>1075</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 21:55:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broyer M, on behalf of the study group</AU>
<TI>A multi-centre open, randomized, controlled study evaluating the effect of growth hormone therapy in short children after renal transplantation [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C49</PG>
<IDENTIFIERS MODIFIED="2011-11-16 21:55:14 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-12 11:52:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Broyer M</AU>
<TI>Results and side-effects of treating children with growth hormone after kidney transplantation - a preliminary report. Pharmacia &amp; Upjohn Study Group</TI>
<SO>Acta Paediatrica Supplement</SO>
<YR>1996</YR>
<VL>417</VL>
<PG>76-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9055918"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-12 11:52:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guest G, Berard E, Crosnier H, Chevallier T, Rappaport R, Broyer M</AU>
<TI>Effects of growth hormone in short children after renal transplantation</TI>
<SO>Pediatric Nephrology</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>6</NO>
<PG>437-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9745864"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Callis-1996-_x0028_preD_x0029_" MODIFIED="2011-11-16 21:56:16 +1100" MODIFIED_BY="[Empty name]" NAME="Callis 1996 (preD)" YEAR="1996">
<REFERENCE MODIFIED="2011-11-16 21:56:16 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Callis LL, del Valle CJ, Garcia L, Garcia Nieto V, Gonzalez Diaz JP, Heras M, et al</AU>
<TI>Randomized open multicentre study to assess treatment with recombinant human growth hormone in children with low height and chronic renal insufficiency [abstract]</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1996</YR>
<VL>45</VL>
<NO>3</NO>
<PG>328</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fine-1994-_x0028_preD_x0029_" MODIFIED="2011-05-12 11:46:59 +1000" MODIFIED_BY="[Empty name]" NAME="Fine 1994 (preD)" YEAR="1994">
<REFERENCE MODIFIED="2011-05-12 11:46:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN, Attie KM, Kuntze J, Brown DF, Kohaut EC</AU>
<TI>Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Genentech Collaborative Study Group</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>451-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7577408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN, Kohaut EC, Brown D, Perlman AJ</AU>
<TI>Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>3</NO>
<PG>374-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8120705"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fine-2002-_x0028_TP_x0029_" MODIFIED="2008-10-01 17:54:11 +1000" MODIFIED_BY="[Empty name]" NAME="Fine 2002 (TP)" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E</AU>
<TI>Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>2</NO>
<PG>688-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12110034"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" MODIFIED="2011-11-16 21:56:42 +1100" MODIFIED_BY="[Empty name]" NAME="Hertel 2002 (preD/Dial)" YEAR="2002">
<REFERENCE MODIFIED="2011-11-16 21:56:42 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hertel NT, Holmberg C, Rönnholm KAR, Jacobsen BB, Ølgaard, Meeuwisse GW, et al</AU>
<TI>Recombinant human growth hormone treatment, using two dose regimens in children with chronic renal failure--a report on linear growth and adverse effects</TI>
<SO>Journal of Pediatric Endocrinology</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>5</NO>
<PG>577-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12014516"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" MODIFIED="2011-12-29 15:36:59 +1100" MODIFIED_BY="[Empty name]" NAME="Hokken-K 1991 (preD/Dial)" YEAR="1991">
<REFERENCE MODIFIED="2011-05-19 14:31:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J</AU>
<TI>Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency</TI>
<SO>Pediatric Nephrology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>7</NO>
<PG>701-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10912546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 21:58:08 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Hokken-Koelega AC. Stijnen T. de Muinck Keizer-Schrama SM. Wit JM. Wolff ED. de Jong MC. Donckerwolcke RA. Abbad NC. Bot A.&lt;br&gt;Blum WF. Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. [Clinical Trial. Journal&lt;br&gt;Article. Randomized Controlled Trial] Lancet. 338(8767):585-90, 1991&lt;/p&gt;" NOTES_MODIFIED="2011-11-16 21:58:08 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Wit JM, Wolff ED, de Jong MC, et al</AU>
<TI>Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8767</NO>
<PG>585-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1715501"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-29 15:36:59 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Graaff LC, Mulder PG, Hokken-Koelega AC</AU>
<TI>Body proportions before and during growth hormone therapy in children with chronic renal failure</TI>
<SO>Pediatric Nephrology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>7</NO>
<PG>679-84</PG>
<IDENTIFIERS MODIFIED="2011-12-29 15:36:59 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="12734746"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" MODIFIED="2011-12-29 15:57:02 +1100" MODIFIED_BY="[Empty name]" NAME="Hokken-K 1994 (preD/Dial)" YEAR="1994">
<REFERENCE MODIFIED="2011-05-19 14:31:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J</AU>
<TI>Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency</TI>
<SO>Pediatric Nephrology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>7</NO>
<PG>701-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10912546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 21:58:34 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Hokken-Koelega AC. Stijnen T. De Jong MC. Donckerwolcke RA. De Muinck Keizer-Schrama SM. Blum WF. Drop SL. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Clinical Endocrinology &amp;amp; Metabolism. 79(4):1185-90, 1994&lt;/p&gt;" NOTES_MODIFIED="2011-11-16 21:58:34 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega AC, Stijnen T, de Jong MC, Donckerwolcke RA, de Muinck Keizer-Schrama SM, Blum WF, et al</AU>
<TI>Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1994</YR>
<VL>79</VL>
<NO>4</NO>
<PG>1185-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7525628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-01 17:57:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Graaff LC, Mulder PG, Hokken-Koelega AC</AU>
<TI>Body proportions before and during growth hormone therapy in children with chronic renal failure</TI>
<SO>Pediatric Nephrology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>7</NO>
<PG>679-84</PG>
<IDENTIFIERS MODIFIED="2008-10-01 17:57:51 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="12734746"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" MODIFIED="2011-12-29 15:36:42 +1100" MODIFIED_BY="[Empty name]" NAME="Hokken-K 1994 (TP)" YEAR="1994">
<REFERENCE MODIFIED="2011-11-16 21:58:54 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Hokken-Koelega AC. Stijnen T. de Ridder MA. de Muinck Keizer-Schrama SM. Wolff ED. de Jong MC. Donckerwolcke RA. Groothoff JW. Blum WF. Drop SL. Growth hormone treatment in growth-retarded adolescents after renal transplant. [Clinical Trial. Journal Article. Randomized Controlled Trial] Lancet. 343(8909):1313-7, 1994 May 28.&lt;/p&gt;" NOTES_MODIFIED="2011-11-16 21:58:54 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega AC, Stijnen T, de Ridder MA, de Muinck Keizer-Schrama SM, Wolff ED, de Jong MC, et al</AU>
<TI>Growth hormone treatment in growth-retarded adolescents after renal transplant</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8909</NO>
<PG>1313-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7910322"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" MODIFIED="2011-11-16 21:59:08 +1100" MODIFIED_BY="[Empty name]" NAME="Hokken-K 1996 (TP)" YEAR="1996">
<REFERENCE MODIFIED="2011-11-16 21:59:08 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Hokken-Koelega AC. Stijnen T. de Jong RC. Donckerwolcke RA. Groothoff JW. Wolff ED. Blum WF. de Muinck Keizer-Schrama SM. Drop SL. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant. [Clinical Trial. Journal Article. Randomized Controlled Trial] Kidney International - Supplement. 53:S128-34, 1996 Jan&lt;/p&gt;" NOTES_MODIFIED="2011-11-16 21:59:08 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hokken-Koelega AC, Sitjnen T, de Jong RC, Donckerwolcke RA, Groothoff JW, Wolff ED, et al</AU>
<TI>A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant</TI>
<SO>Kidney International - Supplement</SO>
<YR>1996</YR>
<VL>53</VL>
<PG>128-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8771007"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-1997-_x0028_TP_x0029_" MODIFIED="2011-11-16 22:00:09 +1100" MODIFIED_BY="[Empty name]" NAME="Ito 1997 (TP)" YEAR="1997">
<REFERENCE MODIFIED="2011-11-16 22:00:09 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H and Multicenter Study Group of GH in Japan</AU>
<TI>A wide applicability of growth hormone (Genotrophin) to growth impairment in children suffering from various renal diseases [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H, Shizume K, Hibi I</AU>
<TI>The effects of recombinant human growth hormone (r-hGH, SM-9500, genotropin) on growth disturbance in children after renal transplantation. Japanese Multi-Center Study (Genotropin) Group on Children with Renal Disease</TI>
<SO>Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>3</NO>
<PG>194-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7731108"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-01 17:58:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H</AU>
<TI>The use of recombinant human GH (rhGH) in growth failure in children with various renal diseases</TI>
<SO>Clinical Pediatric Endocrinology</SO>
<YR>1997</YR>
<VL>6 Suppl</VL>
<NO>9</NO>
<PG>49-53</PG>
<IDENTIFIERS MODIFIED="2008-10-01 17:58:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-01 17:58:12 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1998192189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-21 17:35:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi H, Ito K</AU>
<TI>rhGH use in children with CRI and undergoing dialysis post-transplant in Japan: A multicentre study</TI>
<SO>British Journal of Clinical Practice Supplement</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>Supplement 1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" MODIFIED="2011-12-29 16:01:02 +1100" MODIFIED_BY="[Empty name]" NAME="Kitagawa 1997 (Dial)" YEAR="1997">
<REFERENCE MODIFIED="2011-11-16 22:01:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H and Japanese Multicenter Study Group</AU>
<TI>A dose modifying effects of growth hormone (GH:NN-798, Norditrophin) in children with chronic renal insufficiency (CRI) [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-04 10:29:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H</AU>
<TI>The use of recombinant human GH (rhGH) in growth failure in children with various renal diseases</TI>
<SO>Clinical Pediatric Endocrinology</SO>
<YR>1997</YR>
<VL>6 Suppl</VL>
<NO>9</NO>
<PG>49-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="1998192189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-29 16:01:02 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi H, Ito K</AU>
<TI>rhGH use in children with CRI and undergoing dialysis post-transplant in Japan: A multicentre study</TI>
<SO>British Journal of Clinical Practice. Supplement</SO>
<YR>1996</YR>
<VL>85</VL>
<PG>26-31</PG>
<IDENTIFIERS MODIFIED="2011-12-29 16:00:58 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-12-29 16:00:58 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8995025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kitagawa T, Ito K, Ito H, Sakai T, Wada H, Kajiwara N</AU>
<TI>GH treatment of children with chronic renal insufficiency: A Japanese clinical trial</TI>
<SO>Clinical Pediatric Endocrinology</SO>
<YR>1997</YR>
<VL>6 Suppl</VL>
<NO>10</NO>
<PG>73-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998182276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitagawa-1997-_x0028_preD_x0029_" MODIFIED="2011-12-29 16:00:26 +1100" MODIFIED_BY="[Empty name]" NAME="Kitagawa 1997 (preD)" YEAR="1997">
<REFERENCE MODIFIED="2011-12-29 15:34:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H and Japanese Multicenter Study Group</AU>
<TI>A dose modifying effects of growth hormone (GH:NN-798, Norditrophin) in children with chronic renal insufficiency (CRI) [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-04 10:29:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito K, Kawaguchi H</AU>
<TI>The use of recombinant human GH (rhGH) in growth failure in children with various renal diseases</TI>
<SO>Clinical Pediatric Endocrinology</SO>
<YR>1997</YR>
<VL>6 Suppl</VL>
<NO>9</NO>
<PG>49-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="1998192189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-29 16:00:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kawaguchi H, Ito K</AU>
<TI>rhGH use in children with CRI and undergoing dialysis post-transplant in Japan: A multicentre study</TI>
<SO>British Journal of Clinical Practice. Supplement</SO>
<YR>1996</YR>
<VL>85</VL>
<PG>26-31</PG>
<IDENTIFIERS MODIFIED="2011-12-29 16:00:15 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-12-29 16:00:15 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8995025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-01 17:58:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kitagawa T, Ito K, Ito H, Sakai T, Wada H, Kajiwara N</AU>
<TI>GH treatment of children with chronic renal insufficiency: A Japanese clinical trial</TI>
<SO>Clinical Pediatric Endocrinology</SO>
<YR>1997</YR>
<VL>6 Suppl</VL>
<NO>10</NO>
<PG>73-80</PG>
<IDENTIFIERS MODIFIED="2008-10-01 17:58:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-01 17:58:24 +1000" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1998182276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuizon-1998-_x0028_Dial_x0029_" MODIFIED="2011-11-16 22:02:34 +1100" MODIFIED_BY="[Empty name]" NAME="Kuizon 1998 (Dial)" YEAR="1998">
<REFERENCE MODIFIED="2011-11-16 22:02:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kuizon BD, Goodman WG, Gales B, Juppner H, Salusky IB</AU>
<TI>Effects of growth hormone on bone and mineral metabolism in dialyzed children [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>546-7</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:02:13 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:02:34 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuizon BD, Goodman WG, Gales B, Sahney S, Juppner H, Salusky IB</AU>
<TI>Growth hormone therapy inhibits the suppressive effects of calcitriol on bone in patients with secondary hyperparathyroidism [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>C48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-21 17:29:35 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-21 17:29:35 +1000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00004340"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxwell-1998a-_x0028_TP_x0029_" MODIFIED="2008-10-01 17:55:49 +1000" MODIFIED_BY="[Empty name]" NAME="Maxwell 1998a (TP)" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell H, Rees L</AU>
<TI>Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>6</NO>
<PG>481-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10210991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxwell-1998b-_x0028_TP_x0029_" MODIFIED="2011-12-29 15:35:06 +1100" MODIFIED_BY="[Empty name]" NAME="Maxwell 1998b (TP)" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell H, Rees L</AU>
<TI>Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>6</NO>
<PG>481-87</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10210991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powell-1997-_x0028_preD_x0029_" MODIFIED="2011-12-29 16:02:54 +1100" MODIFIED_BY="[Empty name]" NAME="Powell 1997 (preD)" YEAR="1997">
<REFERENCE MODIFIED="2011-12-29 16:01:36 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brewer ED, Ou C, Hogg RJ</AU>
<TI>Glomerular filtration rate (GFR) in children with advanced chronic renal failure (CRF) during short term therapy with growth hormone (rhGH)-- a multicenter trial of the southwest pediatric nephrology study group (SPNSG) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:03:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell DR, Attie K,Hintz RL, Liu F, Baker B, Kuntze J, et al</AU>
<TI>Growth hormone stimulates growth and alters the serum insulin-growth factor axis of children with chronic renal failure: Report of the Southwest Pediatric Nephrology Study Group [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-29 16:02:54 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell DR, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ, et al</AU>
<TI>Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the Southwest Pediatric Nephrology Study Group</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1999</YR>
<VL>84</VL>
<NO>2</NO>
<PG>596-601</PG>
<IDENTIFIERS MODIFIED="2011-12-29 16:02:54 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-12-29 16:02:54 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10022422"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:04:34 +1100" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Powell DR. Liu F. Baker BK. Hintz RL. Lee PD. Durham SK. Brewer ED. Frane JW. Watkins SL. Hogg RJ. Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Kidney International. 51(6):1970-9, 1997 Jun&lt;/p&gt;" NOTES_MODIFIED="2011-11-16 22:04:34 +1100" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Powell DR, Liu F, Baker BK, Hintz RL, Lee PD, Durham SK, et al</AU>
<TI>Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group</TI>
<SO>Kidney International</SO>
<YR>1997</YR>
<VL>51</VL>
<NO>6</NO>
<PG>1970-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9186890"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:04:58 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watkins SL, Hogg RJ, Brewer ED, Powell DR, Boechat I, Brown D, et al</AU>
<TI>Bone mineral parameters in children with chronic renal fialure (CRF) receiving recombinant human growth hormone (GH). A report of the Southwest Pediatric Nephrology Group. [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>C51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-2002-_x0028_TP_x0029_" MODIFIED="2011-12-29 16:04:38 +1100" MODIFIED_BY="[Empty name]" NAME="Sanchez 2002 (TP)" YEAR="2002">
<REFERENCE MODIFIED="2011-12-29 16:04:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanchez CP, Goodman WG, Kuison BD, Gales B, Malekzadeh M, Saluusky IB</AU>
<TI>Growth hormone and bone: A randomised prospective study</TI>
<SO>16th Annual Meeting. American Society of Transplant Physicians; 1997 May 10-14; Chicago (USA)</SO>
<YR>1997</YR>
<PG>156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-02 21:13:44 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez CP, Goodman WG, Kuizon BD, Ettenger RB, Salusky IB</AU>
<TI>Growth response to growth hormone therapy varies with bone histology in pediatric renal transplant recipients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Progams &amp; Abstracts</NO>
<PG>550</PG>
<IDENTIFIERS MODIFIED="2011-11-02 21:13:35 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:05:26 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez CP, Kuizon BD, Goodman WG, Gales B, Ettenger RB, Inez Boechat M, et al</AU>
<TI>Growth hormone and the skeleton in pediatric renal allograft recipients</TI>
<SO>Pediatric Nephrology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>322-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12042887"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-16 22:07:25 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez CP, Salem M, Ettenger RB</AU>
<TI>Changes in cyclosporine A levels in pediatric renal allograft recipients receiving recombinant human growth hormone therapy</TI>
<SO>Transplantation Proceedings</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>8</NO>
<PG>2807-10</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:07:25 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:07:25 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11134812"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-28 12:59:19 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-28 12:59:19 +1000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00004340"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" MODIFIED="2011-12-29 14:15:24 +1100" MODIFIED_BY="[Empty name]" NAME="Santos 2010 (preD/Dial)" YEAR="2010">
<REFERENCE MODIFIED="2011-12-29 14:15:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno L, Santos F, Neto A, Ariceta G, Vara J, Alonso A, et al</AU>
<TI>Improvement in growth after one year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: results of a multi-center, controlled, randomized, open clinical trial [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>790</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-29 14:14:54 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santos F, Moreno ML, Neto A, Ariceta G, Vara J, Alonso A, et al</AU>
<TI>Improvement in growth after 1 year of growth hormone therapy in well-nourished infants with growth retardation secondary to chronic renal failure: Results of a multicenter, controlled, randomized, open clinical trial</TI>
<SO>Clinical Journal of the American Society of Nephrology</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>7</NO>
<PG>1190-7</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:08:08 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-16 22:08:08 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="20522533"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-02-15 13:01:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-02-15 13:01:36 +1100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00184769"/>
</IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-12-29 16:05:30 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ghio-2002-_x0028_TP_x0029_" MODIFIED="2011-07-23 14:28:40 +1000" MODIFIED_BY="[Empty name]" NAME="Ghio 2002 (TP)" YEAR="2002">
<REFERENCE MODIFIED="2011-07-23 14:28:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghio L, Damiani B, Garavaglia R, Oppizzi G, Taioli E, Edefonti A</AU>
<TI>Lipid profile during rhGH therapy in pediatric renal transplant patients</TI>
<SO>Pediatric Transplantation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>2</NO>
<PG>127-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12000468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jedrzejowski-2002" NAME="Jedrzejowski 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jedrzejowski A, Panczyk-Tomaszewska M, Roszkowska-Blaim M, Lis D, Galazka B, Dyras P</AU>
<TI>Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis</TI>
<SO>Pediatric Nephrology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>10</NO>
<PG>830-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12376812"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laine-1995" MODIFIED="2011-12-29 16:05:30 +1100" MODIFIED_BY="Narelle S Willis" NAME="Laine 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-12-29 16:05:30 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laine J, Krogerus L, Sipila I, Ronnholm K, Holmberg C</AU>
<TI>Effects of recombinant human growth hormone treatment of renal allograft function and histopathology [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>6</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-05-19 12:52:41 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-12-29 14:42:46 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-12-29 14:08:18 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Berard-2008" MODIFIED="2011-11-16 22:09:41 +1100" MODIFIED_BY="[Empty name]" NAME="Berard 2008" TYPE="JOURNAL_ARTICLE">
<AU>Berard E, Andre JL, Guest G, Berthier F, Afanetti M, Cochat P, et al</AU>
<TI>Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology</TI>
<SO>Pediatric Nephrology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>11</NO>
<PG>2031-8</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:09:41 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:09:41 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18584215"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clayton-2000" MODIFIED="2011-11-16 22:09:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="Clayton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Clayton PE, Cowell CT</AU>
<TI>Safety issues in children and adolescents during Growth Hormone Therapy - a review</TI>
<SO>Growth Hormone &amp; IgF Research</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>6</NO>
<PG>306-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11161961"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cowell-1995" NAME="Cowell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cowell CT, Dietsch S</AU>
<TI>Adverse events during growth hormone therapy</TI>
<SO>Journal of Pediatric Endocrinology &amp; Metabolism</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>4</NO>
<PG>243-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8821900"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1995" NAME="Dickersin 1995" TYPE="BOOK_SECTION">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>Systematic Reviews</SO>
<YR>1995</YR>
<PG>17-36</PG>
<ED>Chalmers I, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Disney-1999" NAME="Disney 1999" TYPE="BOOK">
<AU>Disney APS, Russ GR, Walker R, Sheil AGR, Collins J, Herbert K , Kerr P</AU>
<SO>ANZDATA Registry Report 1999</SO>
<YR>1999</YR>
<PB>Australia and New Zealand Dialysis and Transplant Registry</PB>
<CY>Adelaide</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fine-1995a" NAME="Fine 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN</AU>
<TI>Recombinant human growth hormone (rhGH) in dialysis patient: update 1995</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>261-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8534718"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fine-2005" NAME="Fine 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN, Stablein D</AU>
<TI>Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry</TI>
<SO>Pediatric Nephrology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>404-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15682317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fine-2010" MODIFIED="2011-11-16 22:11:12 +1100" MODIFIED_BY="[Empty name]" NAME="Fine 2010" TYPE="JOURNAL_ARTICLE">
<AU>Fine RN, Martz K, Stablein D</AU>
<TI>What have 20 years of data from the North American Pediatric Renal Transplant Cooperative Study taught us about growth following renal transplantation in infants, children and adolescents with end-stage renal disease?</TI>
<SO>Pediatric Nephrology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>4</NO>
<PG>739-46</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:11:11 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:11:11 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20013293"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haffner-2000" NAME="Haffner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Haffner D, Schaefer F, Nissel R, Wuhl E, Tönshoff B, Mehls O</AU>
<TI>Effect of growth hormone treatment on the adult height of children with chronic renal failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>13</NO>
<PG>923-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11006368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-12-29 14:08:18 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-K_x002f_DOQI-2002" NAME="K/DOQI 2002" TYPE="JOURNAL_ARTICLE">
<AU>National Kidney Foundation. K/DOQI Workgroup</AU>
<TI>K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2 Suppl 1</NO>
<PG>1-266</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11904577"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre D, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomised controlled trials in Embase</TI>
<SO>Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)</SO>
<YR>1996</YR>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moyer-1998" MODIFIED="2011-11-16 22:14:28 +1100" MODIFIED_BY="[Empty name]" NAME="Moyer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-613</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:14:28 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:14:28 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9746022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pettiti-1994" NAME="Pettiti 1994" TYPE="BOOK">
<AU>Pettiti DB</AU>
<SO>Meta-analysis decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine</SO>
<YR>1994</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Postlethwaite-1998" NAME="Postlethwaite 1998" TYPE="JOURNAL_ARTICLE">
<AU>Postlethwaite RJ, Eminson DM, Reynolds JM, Wood AJ, Hollis S</AU>
<TI>Growth in renal failure: a longitudinal study of emotional and behavioural changes during trials of growth hormone treatment</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>3</NO>
<PG>222-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9613351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reeves-2002" MODIFIED="2011-11-16 22:17:03 +1100" MODIFIED_BY="[Empty name]" NAME="Reeves 2002" TYPE="JOURNAL_ARTICLE">
<AU>Reeves GD, Doyle DA</AU>
<TI>Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship?</TI>
<SO>Journal of Pediatric Endocrinology</SO>
<YR>2002</YR>
<VL>15 Suppl 2</VL>
<PG>723-30</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:17:03 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:17:03 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12092686"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1995" NAME="Reynolds 1995" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds JM, Wood AJ, Eminson DM, Postlethwaite RJ</AU>
<TI>Short stature and chronic renal failure: what concerns children and parents</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7639547"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rizzoni-1985" MODIFIED="2011-11-16 22:17:36 +1100" MODIFIED_BY="[Empty name]" NAME="Rizzoni 1985" TYPE="CONFERENCE_PROC">
<AU>Rizzoni G, Broyer M, Brunner FP, Brynger H, Challah S, Kramer P, et al</AU>
<TI>Combined report on regular dialysis and transplantation of children in Europe, XIII, 1983</TI>
<SO>Proceedings of the European Dialysis &amp; Transplant Association - European Renal Association</SO>
<YR>1985</YR>
<VL>21</VL>
<PG>66-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3887379"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-T_x00f6_nshoff-1995" MODIFIED="2011-11-16 22:18:05 +1100" MODIFIED_BY="[Empty name]" NAME="Tönshoff 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tönshoff B, Mehls O</AU>
<TI>Growth retardation in children with chronic renal insufficiency: current aspects of pathophysiology and treatment</TI>
<SO>Journal of Nephrology</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>3</NO>
<PG>133-42</PG>
<IDENTIFIERS MODIFIED="2011-11-16 22:18:05 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-11-16 22:18:05 +1100" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1995200628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilton-1999" NAME="Wilton 1999" TYPE="BOOK_SECTION">
<AU>Wilton P</AU>
<TI>Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey</TI>
<SO>Progress in growth hormone therapy - 10 years of KIGS</SO>
<YR>1999</YR>
<PG>349-64</PG>
<ED>Ranke MB, Wilton P</ED>
<PB>Ja Barh Verlag</PB>
<CY>Mannheim</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-W_x00fc_hl-1996" NAME="Wühl 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wühl E, Haffner N, Nissel R, Schaefer F, Mehls O and German Study Group for Growth Hormone Treatment in Chronic Renal Failure</AU>
<TI>Short dialyzed children respond less to growth hormone than patients prior to dialysis</TI>
<SO>Pediatric Nephrology</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>294-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8792393"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-12-29 14:42:46 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Vimalachandra-2001a" MODIFIED="2008-10-01 18:01:56 +1000" MODIFIED_BY="[Empty name]" NAME="Vimalachandra 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Vimalachandra D, Craig JC, Cowell C, Knight JF</AU>
<TI>Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials</TI>
<SO>Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>139</VL>
<NO>4</NO>
<PG>560-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11598604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vimalachandra-2001b" MODIFIED="2008-10-01 18:01:45 +1000" MODIFIED_BY="[Empty name]" NAME="Vimalachandra 2001b" TYPE="COCHRANE_REVIEW">
<AU>Vimalachandra D, Craig JC, Cowell C, Knight JF</AU>
<TI>Growth hormone for children with chronic renal failure</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-01 18:01:43 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-01 18:01:43 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003264"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vimalachandra-2006" MODIFIED="2011-12-29 14:42:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="Vimalachandra 2006" TYPE="COCHRANE_REVIEW">
<AU>Vimalachandra D, Hodson EM, Willis NS, Craig JC, Cowell CT, Knight JF</AU>
<TI>Growth hormone for children with chronic kidney disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-12-29 14:42:45 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2011-12-29 14:42:45 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD003264.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-01 17:29:26 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-01 17:28:40 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-01-01 14:44:00 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-15 19:24:21 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: November 1990 to April 1994</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:44:00 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre tertiary centres</LI>
<LI>Country: France, Belgium, Switzerland, Portugal, Sweden, United Kingdom, Hungary, Argentina, Australia, New Zealand</LI>
<LI>Kidney transplant recipients at least 1 year post transplant with normal serum thyroid hormone levels; HSDS for CA below -2 or growth velocity &lt; 25th percentile for age with 2 separate measurement in &#8805; 6 months before entry; GFR &gt; 20 mL/min/1.73 m², pubertal (testicular volume 4 &#8804; 8 mL, breast development B2 &#8804; B3) (86) or prepubertal (testicular volume &lt; 4 mL, breast development &lt; B2) (86)</LI>
<LI>Number</LI>
<UL>
<LI>Treatment group: 106 enrolled (67 prepubertal) (66 evaluated for height and 92 for GFR overall; 41/44 French children)</LI>
<LI>Control group: 97 enrolled (51 prepubertal) (59 evaluated for height and 88 for GFR overall; 44/46 French children)</LI>
</UL>
<LI>Age (mean ± SD): treatment group (12.1 ± 3.1 years); control group (12.6 ± 3.3 years)</LI>
<LI>Sex (M/F): treatment group (72/25); control group (71/35)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Other chronic illness; height velocity &#8805;75th percentile; dialysis therapy; malignancy; treatment with rhGH in previous 12 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-15 16:47:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH </LI>
<LI>Dose: 30 IU/m²/wk in divided daily doses SC</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Prednisone, azathioprine, cyclosporin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-01 13:18:04 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity</LI>
<LI>Change in BA</LI>
<LI>Adverse effects: change in GFR; acute rejection episodes</LI>
<LI>Follow-up at 1 year: 61% overall, 94% of 90 children included in report of French children</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 15:55:36 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported separately</LI>
<LI>Exclusions after intervention administered</LI>
<UL>
<LI>125/203 entered were evaluated for height and 180/203 entered evaluated for GFR</LI>
<LI>23 excluded from kidney function analysis as GFR &lt; 20, transplanted &lt; 12 months, rhGH started without randomisation or therapy not complied with.</LI>
<LI>49 excluded from growth analysis due to abnormal thyroid function, GV too high, HSDS at entry &lt; -2 SDS, previous growth not documented.</LI>
</UL>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: no</LI>
<LI>Data on 90 patients from French centres, which took part in international multicentre study entering 203 patients, included in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> and <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>. Data from 125/203 patients included in <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> and <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>
</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 13:18:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<CHAR_METHODS MODIFIED="2011-11-15 19:24:12 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:47:33 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre tertiary centres</LI>
<LI>Country: Spain</LI>
<LI>CKD with GFR &lt; 50 mL/min/1.73 m²; height: SDS &gt; - 2SDS or growth velocity &lt; 50th percentile for CA; prepubertal using Tanner criteria; normal TSH levels and GH levels post stimulation &#8805; 10 ng/mL</LI>
<LI>Number: treatment group 1 (23): treatment group 2 (21)</LI>
<LI>Age (mean ± SD): treatment group 1 (8.7 ± 2.8 years); treatment group 2 (8.7 ± 3.8 years)</LI>
<LI>Sex (M/F): treatment group 1 (17/6); treatment group 2 (16/5)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-29 14:46:03 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:47:54 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in HSDS</LI>
<LI>Height velocity (cm/y)</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 96%; 2 patients excluded from analysis because of protocol violation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-01 13:18:09 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Exclusions after intervention administered</LI>
<UL>
<LI>2/46 children not included in analysis because of protocol violation</LI>
<LI>34 completed 1 year of follow-up</LI>
</UL>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:44:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<CHAR_METHODS MODIFIED="2011-11-15 19:23:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: April 1988 to June 1990</LI>
<LI>Follow-up period: 24 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:44:38 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre tertiary centres</LI>
<LI>Country: USA</LI>
<LI>CKD with CrCl &gt; 5 and &lt; 75 mL/min/1.73 m²; height: &lt; 3rd percentile for CA; prepubertal (BA &lt; 10 (girls), &lt; 11 (boys))</LI>
<LI>Number</LI>
<UL>
<LI>Treatment group: 82 enrolled (69 completed 1 year and 55 completed 2 years). 55 included in results</LI>
<LI>Control group: 43 enrolled (30 completed 1 year, 27 completed 2 years). 27 included in results</LI>
</UL>
<LI>Age (mean ± SD): treatment group (6.0 ± 3.9 years); control group (5.7 ± 3.6 years)</LI>
<LI>Sex (M/F): treatment group (61/21); control group (28/14; 1 patient unaccounted for)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Cause for growth retardation not CKD; inability to measure accurately; steroid use; DM; malignant disease; other investigational drug</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-15 17:15:32 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk (0.05 mg/kg/d SC). Dose adjusted for weight every 3 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>Dose: equivalent volume SC daily</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin D; phosphate binder; prophylactic antibiotics; antihypertensive agents</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:50:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Height velocity (cm/y)</LI>
<LI>Change in BA</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: at 1 year (80%); at 2 years (67%)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:48:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Exclusions after intervention administered</LI>
<UL>
<LI>Treatment group</LI>
<UL>
<LI>Excluded in 1st year (13): adverse events (2); non compliance (4); transplant (2); request (5)</LI>
<LI>Excluded in 2nd year (13): adverse events (2); lost to follow-up (1); transplant (9); request (1)</LI>
</UL>
<LI>Placebo group</LI>
<UL>
<LI>Excluded in 1st year (12): adverse events (1); non compliance (2); transplant (4); request (3); protocol violation (1); precocious puberty (1)</LI>
<LI>Excluded in 2nd year (3): transplant (2); request (1)</LI>
</UL>
</UL>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:45:15 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-15 19:25:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: December 1996 to June 2000</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:45:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: tertiary, multicentre</LI>
<LI>Country: USA</LI>
<LI>Kidney transplant recipients; no rejection requiring change of therapy in previous 6 months; transplant for &gt; 1 year; HSDS: &lt; -2; BA: &lt; 16 years (M) &lt; 15 years (F)</LI>
<LI>Number: treatment group (36 enrolled; 5 withdrawn during study); control group (27 enrolled; 5 withdrawn during study)</LI>
<LI>Age (range): treatment group (5-16 years); control group (5-16 years)</LI>
<LI>Sex (M/F): treatment group (25/2); control group (29/7)</LI>
<LI>Pubertal stage: treatment group (1 in 26; 2-3 in 10); control group (1 in 14; 2-3 in 13)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Other protocols or investigational drugs; specific cause for growth retardation; malignancy; DM; oestrogen/androgen therapy; inability to measure</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-15 19:32:01 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH (Nutropin) </LI>
<LI>Dose: 28 IU/m²/wk</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Prednisone &lt; 0.15 mg/kg/d or &lt; 0.25 mg/kg on alternate days; centre-specific immunosuppression</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:50:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in growth velocity (cm/y)</LI>
<LI>Adverse events</LI>
<LI>Follow-up at 1 year: 84%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:49:23 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: treatment group (3); control group (2)</LI>
<LI>Exclusions after intervention: treatment group (5); control group (5)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: additional information on HSDS obtained from authors</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:48:58 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-11-15 19:39:26 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:48:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: tertiary, multicentre</LI>
<LI>Country: Denmark, Sweden and Finland</LI>
<LI>Pre-dialysis (GFR &lt; 40 mL/min/1.73m²) and dialysis patients; CKD &gt; 1 year; CA (3-18 years); HSDS (&lt; -2) and HVSDS below mean for age/sex or HSDS below mean and HVSDS &lt; 0.68 SD for CA; prepubertal (BA &lt; 12 years (M), &lt; 10 years (F))</LI>
<LI>Number: treatment group 1 (14 enrolled; 14 evaluated for 1+ outcomes); treatment group 2 (15 enrolled; 12 evaluated for 1+ outcomes)</LI>
<LI>Age (mean; range): treatment group 1 (10.3 years; 3.6-15.1); treatment group 2 (9.7 years; 3.4-15.0)</LI>
<LI>Sex (M/F): treatment group 1 (12/2); treatment group 2 (12/3)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Abnormal thyroid function; endocrine/metabolic disease; growth retardation due to other physical disease or psychosocial</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 16:38:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH (norditrophin)</LI>
<LI>Dose: 28 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:50:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in HVSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Carbohydrate metabolism</LI>
<LI>Blood pressure and GFR</LI>
<LI>Adverse events</LI>
<LI>Follow-up at 1 year: 79%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:50:42 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Exclusions after intervention: 6 (treatment groups NS)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:52:02 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 15:59:40 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over study</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months (data taken from first 6 months)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:50:55 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre tertiary centres</LI>
<LI>Country: Netherlands</LI>
<LI>CKD (9) and ESKD (11; GFR &lt; 20 mL/min/1.73 m²); HSDS for CA below -1.88; height velocity for CA &lt; 25th percentile; prepubertal</LI>
<LI>Number: treatment group (8); control group (8)</LI>
<LI>Age (mean, range): treatment group (8.7 years, 4.4-11.3); control group (8.6, 4.4-16.0)</LI>
<LI>Sex (M/F): treatment group (6/2); control group (4/4)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Thyroid disease; renal bone disease; previous anabolic steroids, sex steroids or erythropoietin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-29 14:51:07 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk in divided daily doses SC for 6 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>Dose: equal volume of placebo preparation SC for 6 months</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin D, phosphate binders, calcium supplements</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:51:50 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in height velocity</LI>
<LI>Change in height HVSDS</LI>
<LI>Change in bone age</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 80%; excluded because of kidney transplant at 6 months (3) and 7 months (1)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:52:02 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: excluded following kidney transplantation (4)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: no</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:53:04 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 16:08:43 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2.5 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:52:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary centres</LI>
<LI>Country: Netherlands</LI>
<LI>CKD (8) and ESKD (15; GFR &lt; 20mL/min/1.73 m²); prepubertal; HSDS for CA &lt; -1.88 with height velocity for CA &lt; 50th percentile or HSDS for CA &lt; 0.00 with height velocity for CA &lt;50th percentile; BA: &lt; 10 (girls), &lt; 12 (boys)</LI>
<LI>Number: treatment group 1 (12); treatment group 2 (11)</LI>
<LI>Age (mean, range): treatment group 1 (7.5 years, 1.6-14.1); treatment group 2 (6.6 years, 2.7-12.5)</LI>
<LI>Sex (M/F): treatment group 1 (11/1); treatment group 2 (7/4)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Renal bone disease; thyroid dysfunction; metabolic acidosis; previous anabolic steroids or sex steroids</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 16:12:37 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk in divided daily dose SC</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin D, phosphate binders, calcium supplements</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:52:41 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HVSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: at 1 year (78%, 5/23 transplanted); at 2 years (57%, 4 transplanted, 1 died)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:53:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: excluded because of kidney transplant after 6 months (5); excluded in 2nd year because of transplant (4), death (1)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:50:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 16:16:50 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:50:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary centre</LI>
<LI>Country: Netherlands</LI>
<LI>Kidney transplant recipients &gt; 1 year post-transplant; no rejection episodes for 6 months; HSDS &lt; -1.88 and height velocity for CA &lt; 50th percentile or HSDS &gt; -1.88 and height velocity for CA &lt; 25th percentile; prednisone (&lt; 0.25 mg/kg/d or &lt; 0.5 mg/kg/d on alternate days); pubertal</LI>
<LI>Number: treatment group 1 (7 enrolled; 5 early puberty); treatment group 2 (9 enrolled; 5 early puberty)</LI>
<LI>Age (mean ± SD): treatment group 1 (15.7 ± 1.9 years); treatment group 2 (15.5 ± 2.6 years)</LI>
<LI>Sex (M/F): treatment group 1 (4/3); treatment group 2 (5/4)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Thyroid dysfunction; metabolic acidosis; previous sex hormone treatment; growth retardation due to another cause</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-29 14:45:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 56 IU/m²/wk divided into daily doses for 2 years</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for 2 years</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Prednisone (alternate day 10, daily 7, none 1), azathioprine, cyclosporin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:53:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HVSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: did not complete 2 year study (3; returned to dialysis at 15 and 16 months (2)); entered late and completed 18 months (1))</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:53:57 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: did not complete 2 years follow-up (3; 2 returned to dialysis, 1 entered late)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:54:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 16:34:37 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over study</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:54:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: Netherlands</LI>
<LI>Kidney transplant recipients &gt; 1 year post transplant; no rejection episodes for 6 months; HSDS &lt; -1.88 and height velocity for CA &lt; 50th percentile or HSDS &gt; -1.88 and height velocity for CA &lt; 25th percentile; prednisone &lt; 0.25 mg/kg/d for at least 6 months</LI>
<LI>Number: treatment group (6); control group (5)</LI>
<LI>Age (mean, range): treatment group (12.1 years, 9.1-18.7); control group (11.1 years, 8.3-14.9)</LI>
<LI>Sex (M/F): treatment group (9/2), control group (4/1)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Thyroid dysfunction; metabolic acidosis; previous sex hormone treatment; growth retardation due to another cause</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-29 14:45:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for 6 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>Dose: divided into daily doses for 6 months</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Prednisone, azathioprine, cyclosporin</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:54:18 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HVSDS</LI>
<LI>Change in height velocity (cm/6 months)</LI>
<LI>Change in BA in years</LI>
<LI>GFR, effective renal plasma flow</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 100%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:54:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none</LI>
<LI>Stop or end point/s: none reported</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:55:04 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 16:40:21 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:54:36 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: single university centre</LI>
<LI>Country: Japan</LI>
<LI>Kidney transplant recipients; prepubertal or early puberty (BA &lt;14 (boys), 13 (girls)); steroid dose &lt; 0.5 mg/kg/d</LI>
<LI>Number: treatment group 1 (13); treatment group 2 (10)</LI>
<LI>Age (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 16:42:15 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for 1 year</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk divided into daily doses for 1 year</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:54:48 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Height velocity (cm/y)</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 85%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:55:04 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Exclusions post intervention: 27 children included initially, 4 excluded from analysis because of non compliance or poor response to rhGH</LI>
<LI>Stop or end point/s: none reported</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:55:48 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 16:58:47 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:55:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: Japan</LI>
<LI>Children on dialysis; prepubertal (bone age &lt; 13 years (boys), &lt;12 years (girls)); HSDS or HVSDS &lt; -1.5</LI>
<LI>Number: treatment group 1 (28); treatment group 2 (26)</LI>
<LI>Age (mean ± SD): treatment group 1 (10.2 ± 4.3 years); treatment group 2 (9.9 ± 3.2 years)</LI>
<LI>Sex (M/F): treatment group 1 (17/11); treatment group 2 (15/11)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:07:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for up to 2 years</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk divided into daily doses for up to 2 years</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:55:36 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Change in HVSDS</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: at 1 year (88%); at 2 years (57%)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:55:48 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: did not complete 1 year of treatment (6); did not complete 2 years (additional 25)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:56:17 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:09:37 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:55:54 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: Japan</LI>
<LI>Children with CKD (GFR &lt; 40 mL/min/1.73 m²); prepubertal (BA &lt; 13 years (boys), &lt; 12 years (girls)); HSDS or HVSDS &lt; -1.5</LI>
<LI>Number: treatment group 1 (30); treatment group 2 (28)</LI>
<LI>Age (mean ± SD): treatment group 1 (8.7 ± 2.9 years); treatment group 2 (8.6 ± 3.3 years)</LI>
<LI>Sex (M/F): treatment group 1 (22/8); treatment group 2 (19/9)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:12:16 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for up to 2 years</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 14 IU/m²/wk divided into daily doses for up to 2 years</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:56:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Change in HVSDS</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: at 1 year (83%); at 2 years (53%)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:56:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: did not complete 1 year (10); did not complete 2 years (additional 17)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 15:15:59 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-12-29 14:45:20 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year (assumed)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 15:15:59 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: tertiary centre</LI>
<LI>Country: USA</LI>
<LI>Children with ESKD on peritoneal dialysis</LI>
<LI>Age (mean ± SE): 8.4 ± 1.5 years</LI>
<LI>Number: treatment group (6); control group (8)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:20:18 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH </LI>
<LI>Dose: 28 IU/m²/wk SC</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:56:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Growth velocity (cm/y)</LI>
<LI>Loss to follow-up: not reported</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:56:53 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: additional information requested but not available</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:57:28 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:22:15 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:57:06 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: UK</LI>
<LI>Kidney transplant recipients for &gt; 1 year; pubertal; height &lt; 3rd percentile for CA or height velocity &lt; 25th percentile for CA; GFR &gt; 20 mL/min/1.73 m² (GFR 48 (23-78) mL/min/1.73 m²)</LI>
<LI>Number: treatment group (4); control group (3)</LI>
<LI>Mean age (range): 15.2 years, (12.4-19.8)</LI>
<LI>Sex (M/F): 5/2</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Thyroid dysfunction</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:24:47 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for 1 year</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:57:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Change in HVSDS</LI>
<LI>Change in BA</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 100%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:57:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-29 14:58:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:27:26 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-29 14:57:34 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: UK</LI>
<LI>Kidney transplant recipients for &gt; 1 year; prepubertal; height &lt; 3rd percentile for CA or HV &lt; 25th percentile for CA; GFR &gt;20 mL/min/1.73 m² (GFR 51 (13-113) mL/min/1.73 m²)</LI>
<LI>Number: treatment group (9); control group (6)</LI>
<LI>Mean age (range): 13.0 years (9.4-16.5)</LI>
<LI>Sex (M/F): 13/2</LI>
<LI>Age (years): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Thyroid dysfunction</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:32:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk divided into daily doses for 1 year</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:57:44 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Change in HVSDS</LI>
<LI>Change in BA</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 100% (2/9 ceased rhGH after 9 and 11 months but included)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:58:09 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:51:28 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:36:21 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:51:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: USA</LI>
<LI>CKD with GFR 10-40 mL/min/1.73 m²; prepubertal with bone age &lt;11 (boys), &lt;10 (girls); age &gt; 2.5 years; height: &lt; 5th percentile for CA, able to stand for measurements</LI>
<LI>Number: treatment group (46 enrolled; 30 analysed); control group (23 enrolled; 14 analysed)</LI>
<LI>Age (mean ± SD): treatment group (5.6 ± 2.0 years); control group (5.7 ± 2.6 years)</LI>
<LI>Sex (M/F): treatment group (25/5); control group (12/2)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serum albumin &lt; 25g/L; receiving medications that influence growth; other illnesses that affect growth; DM; previous malignancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:41:05 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>28 IU/m²/wk divided into daily doses for 1 year</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:58:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in BA</LI>
<LI>Follow-up: completed study (64%)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:58:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: none reported</LI>
<LI>Exclusions post intervention: exited before 1 year (20; 1 death, 12 to ESKD, 1 allergy to rhGH, 6 entered puberty); excluded because of lack of data (5)</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:52:37 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:43:36 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:52:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Setting: single tertiary unit</LI>
<LI>Country: USA</LI>
<LI>Kidney transplant recipient &gt; 1 year post-transplant; prepubertal; stable kidney function; no previous rhGH; normal bone formation rate or adynamic bone disease on biopsy; agreement to undergo bone biopsy</LI>
<LI>Number: treatment group (12 enrolled; 11 analysed; 1 withdrawn); control group (11 enrolled; 10 evaluated; 1 withdrawn)</LI>
<LI>Age (mean ± SD): treatment group (9.7 ± 4.5 years); control group (11 ± 1.8 years)</LI>
<LI>Sex (M/F): 18/5</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Histological evidence of secondary hyperparathyroidism on bone biopsy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-16 17:47:30 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk (0.05 mg/kg/d given SC) for up to 24 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Cyclosporin, azathioprine, prednisone (0.1 ± 0.04 mg/kg/d)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:59:22 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Change in BA</LI>
<LI>GFR</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: 91%</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:59:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Exclusions post intervention: I patient withdrawn from each group and excluded from analysis</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: additional information on HSDS obtained from authors</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-01 14:53:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<CHAR_METHODS MODIFIED="2011-11-16 17:49:37 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: Every 3 months up to 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-01 14:53:21 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Setting: multicentre tertiary units</LI>
<LI>Country: Spain, Portugal</LI>
<LI>CA (12 ± 3 months); GFR (&#8804; 60 mL/min/1.73 m²) as calculated by Schwartz formula; length below -2 SDS for the same CA and growth velocity below the 50th percentile; conservative treatment or long-term peritoneal dialysis; euthyroid status; nutational intake assessed by dietary records, providing a daily amount of at least 80% of recommended dietary allowances for calories and 10% of calories from high biologic value proteins</LI>
<LI>Number: treatment group (8 enrolled; 7 completed); control group (8 enrolled; 7 completed)</LI>
<LI>Age (mean ± SD): treatment group (14.0 ± 1.7 months); control group (14.4 ± 2.2 months)</LI>
<LI>Sex (M/F): 13/3</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Hormonal, neurologic, osseous, genetic, or nephrologic conditions, other than CKD, that are known to interfere adversely with growth; suspected allergy to the study product; treatment with corticosteroids; inadequate metabolic control of CKD (severe hyper-parathyroidism, sustained metabolic acidosis or sodium or water deficits)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-29 15:56:27 +1100" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>rhGH</LI>
<LI>Dose: 28 IU/m²/wk (0.33 mg/kg/wk) given daily SC at bedtime for up to 12 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: NS</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-29 14:59:56 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in HSDS</LI>
<LI>Change in height velocity (cm/y)</LI>
<LI>Adverse effects</LI>
<LI>Follow-up: completed the study (88%)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-29 14:58:13 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Exclusions post intervention: I patient withdrawn from each group and excluded from analysis due to poor clinical and metabolic control</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BA - bone age; CA - chronological age; CKD - chronic kidney disease; CrCl - creatinine clearance; DM - diabetes mellitus; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; HSDS - height standard deviation score; HVSDS - height velocity standard deviation score; NS - not stated; rhGH - recombinant human growth hormone; SC - subcutaneous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-01 17:29:26 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-01 17:29:16 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghio-2002-_x0028_TP_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-01 17:29:16 +1100" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-01 17:29:21 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jedrzejowski-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-01 17:29:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-01 17:29:26 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Laine-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-01 17:29:26 +1100" MODIFIED_BY="Narelle S Willis">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-05-19 12:52:41 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-01-01 13:18:26 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-16 17:42:48 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:51:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Method not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:48:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:42:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Patients said to be randomly assigned so that one third in placebo group and two thirds in treatment group but no method provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 15:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:03:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 08:50:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:29:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:04:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:53:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:18:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:26:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:11:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:31:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Reported to be randomly assigned but no methodology provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:47:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Patients stratified according to pubertal stage but no information on method of sequence generation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:39:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Patients stratified according to pubertal stage but no information on method of sequence generation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-16 17:42:48 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Method not provided. Groups balanced for age, gender, height, GFR at baseline, primary kidney disease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 15:20:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided but apparently stratified for bone histology (normal bone formation rates or adynamic bone disease)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:14:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Patients stratified for gestational age. No other information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-12-29 15:56:27 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-29 15:55:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"Patients were randomised centrally"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:48:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:39:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-15 19:33:07 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Randomisation into treatment and control groups was performed at the data co-ordinating centre (Emmes Corp.)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:03:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 08:50:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:30:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:04:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:54:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:18:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:26:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:11:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:31:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:47:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:39:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:25:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 15:18:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"A statistician who had no information about the clinical or biochemical characteristics of the study participants randomised the qualified subjects according to initial bone histology finding"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-29 15:56:27 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>"The process of randomisation was centralized at Novo Nordisk"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-04 16:49:43 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-11-16 16:32:07 +1100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:52:56 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No blinding and outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 16:48:40 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No blinding and outcome measurement could influence outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 09:45:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Patients received treatment or placebo in equivalents volumes &amp; both provided by Genetech</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 15:53:32 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No blinding and outcome measurement could be influenced by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 16:04:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No blinding and outcome measurement could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 16:07:29 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>"The children were blindly and randomly assigned to treatment with... or placebo". Trial said to be "double-blind".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 09:30:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"16 were randomly and blindly assigned to one or other dosage"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-19 15:44:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Patients were randomly and blindly assigned to treatment groups. Trial reported to be "double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-16 16:32:07 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"Patients were randomly and blindly assigned". Placebo group received equal volume of injection. Trial reported to be double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:18:36 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 10:26:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 10:13:02 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:34:54 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Control group received no treatment and outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:47:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"Open labelled" trial and outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:40:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>"Open labelled" trial and outcome likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 14:26:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Stated to be "open label". Outcome could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 15:21:36 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No blinding and outcome measurement likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-04 16:15:34 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No blinding and outcome measurement could be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-07-23 14:28:40 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:53:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 16:48:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 09:45:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 15:53:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 16:04:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-19 15:49:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>The same investigator did all the measurements of the children but it was unclear whether this investigator was blinded to treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-19 15:48:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All measurements made by same investigator but unclear whether investigator was blinded to treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-19 15:49:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>The same investigator carried out all height measurements but it was unclear whether this investigator was blinded to treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-19 15:51:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>The same investigator undertook all measurements but it was unclear whether this investigator was blinded to the treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:18:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 10:27:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 10:12:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:35:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:47:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:40:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 14:26:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 15:21:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-04 16:15:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-01-01 13:18:26 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-21 12:27:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Missing data unlikely to influence true outcome (Guest)</P>
<P>If include all data from Broyer - could influence as only 125/203 evaluated for growth and 180/203 for GFR. Unclear when these patients were excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-21 17:21:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Abstract only. 2/46 excluded for protocol violation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-10 16:03:26 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Missing data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-19 16:00:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Missing data (16% rhGH group; 18% control) could introduce clinically relevant bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-15 19:35:52 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>23/29 completed 1 year. 16/29 completed 2 years. Missing data unlikely to influence true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-10 16:26:19 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Missing data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-10 16:29:33 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Missing data not likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-10 16:27:52 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Missing data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-01 13:18:26 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All children completed study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-15 12:26:27 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Missing data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-15 12:24:52 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Missing data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 10:25:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Missing data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 14:33:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Data only available from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 14:47:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All included patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 14:46:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All included patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-15 12:13:40 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Missing data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 15:23:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Missing data unlikely to be related to the true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-04 16:16:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Missing data unlikely to influence outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-07-23 14:28:40 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-21 12:04:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Unclear whether all outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:49:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Abstract only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:02:51 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:02:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All outcomes appear to be reported. Information obtained from authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:23:17 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-19 15:48:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Pre-specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:31:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All outcomes addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 09:22:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Reported pre-specified outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:28:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:19:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information in methods on outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:17:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No details on pre-specified outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:17:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No details on pre-specified outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:33:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>Data only available from abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:47:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All outcomes specified in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:45:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>All outcomes specified in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:28:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Unclear whether all outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 15:25:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Additional information on outcomes obtained from authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 13:09:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-12-29 15:55:49 +1100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:21:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Pharmacia &amp; Upjohn, Stockholm, Sweden</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 16:49:27 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Pharmacia and Upjohn sponsored study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-29 15:55:49 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Funding by Genetech Inc., South San Francisco, Calif..</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:07:57 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by EMMES Corporation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:24:05 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Funding by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:26:51 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Funding by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:30:43 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 16:28:22 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Funding by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:28:29 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:19:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ito-1997-_x0028_TP_x0029_">
<DESCRIPTION>
<P>No information on sponsorship provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:27:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information on sponsorship provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 10:21:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>No information on sponsorship provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-04 14:33:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_">
<DESCRIPTION>
<P>No information on sponsorship provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:19:16 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Action Research and Pharmacia &amp; Upjohn, Stockholm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:17:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Action Research and Pharmacia &amp; Upjohn, Stockholm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:14:18 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_">
<DESCRIPTION>
<P>Funding by Genetech, San Francisco, Calf., USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 12:12:15 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_">
<DESCRIPTION>
<P>Funding by Genetech, San Francisco, Calf., USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-15 13:10:31 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_">
<DESCRIPTION>
<P>Data Management by Novo Nordisk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-01-01 14:41:55 +1100" MODIFIED_BY="Narelle S Willis">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-01-01 14:41:55 +1100" MODIFIED_BY="Narelle S Willis" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-08-25 14:12:00 +1000" MODIFIED_BY="Narelle S Willis">rhGH 28 IU/m²/wk versus placebo/no treatment for children with chronic kidney disease</TITLE>
<TABLE COLS="7" ROWS="30">
<TR>
<TD COLSPAN="7">
<P>
<B>rhGH 28 IU/m²/wk versus placebo/no treatment for children with chronic kidney disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> children with chronic kidney disease<BR/>
<B>Settings:</B> Tertiary Children's Hospitals<BR/>
<B>Intervention:</B> rhGH 28 IU/m²/wk<BR/>
<B>Comparison: </B>Placebo/no specific treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo/no specific treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>rhGH 28 IU/m²/wk </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>HSDS after 1 year of rhGH</B>
<BR/>Follow-up: 6-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean HSDS after 1 year of rhGH in the intervention groups was<BR/>
<B>0.91 higher</B>
<BR/>(0.58 to 1.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>331<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Height velocity (cm/6 mo) after 6 months of rhGH from baseline to 6 months</B>
<BR/>Follow-up: 0-6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean height velocity (cm/6 mo) after 6 months of rhGH from baseline to 6 months in the intervention groups was<BR/>
<B>2.85 higher</B>
<BR/>(2.22 to 3.48 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>27<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Height velocity (cm/y) after 1 year of rhGH</B>
<BR/>Follow-up: 0-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean height velocity (cm/y) after 1 year of rhGH in the intervention groups was<BR/>
<B>3.88 higher</B>
<BR/>(3.32 to 4.44 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>287<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in height velocity SDS from baseline to 6 months</B>
<BR/>Follow-up: 0-6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in height velocity SDS from baseline to 6 months in the intervention groups was<BR/>
<B>7.8 higher</B>
<BR/>(6.09 to 9.51 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>27<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in height velocity SDS from baseline to 1 year</B>
<BR/>Follow-up: 0-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in height velocity SDS from baseline to 1 year in the intervention groups was<BR/>
<B>6.14 higher</B>
<BR/>(3.42 to 8.86 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>22<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> All studies small and generally of low methodological quality</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2012-01-01 14:41:32 +1100" MODIFIED_BY="Narelle S Willis" NO="2" READONLY="YES">
<TITLE MODIFIED="2011-08-25 14:12:14 +1000" MODIFIED_BY="Narelle S Willis">rhGH 28 IU/m²/wk versus 14 IU/m²/wk for children with chronic kidney disease</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>rhGH 28 IU/m²/wk versus 14 IU/m²/wk for children with chronic kidney disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> children with chronic kidney disease<BR/>
<B>Settings:</B> Tertiary Children's Hospitals<BR/>
<B>Intervention:</B> rhGH 28 IU/m²/wk<BR/>
<B>Comparison: </B>rhGH 14 IU/m²/wk</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>rhGH 14 IU/m²/wk</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>rhGH 28 IU/m²/wk </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Final or change in HSDS from baseline to 1 year</B>
<BR/>Follow-up: 0-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean final or change in HSDS from baseline to 1 year in the intervention groups was<BR/>
<B>0.2 higher</B>
<BR/>(0.09 lower to 0.48 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>145<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in height velocity (cm/time period) from baseline to 1 year</B>
<BR/>Follow-up: mean 0-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in height velocity (cm/time period) from baseline to 1 year in the intervention groups was<BR/>
<B>1.18 higher</B>
<BR/>(0.52 to 1.84 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>150<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Change in height velocity SDS from baseline to 1 year</B>
<BR/>Follow-up: 0-12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in height velocity SDS from baseline to 1 year in the intervention groups was<BR/>
<B>1.48 higher</B>
<BR/>(0.03 to 2.93 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>106<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Small studies of poor methodological quality</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-01-01 17:28:06 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-01-01 17:28:06 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Reported adverse effects</TITLE>
<TABLE COLS="2" ROWS="17">
<TR>
<TH>
<P>Studies</P>
</TH>
<TH>
<P>Adverse effects</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Broyer-1996-_x0028_TP_x0029_" TYPE="STUDY">Broyer 1996 (TP)</LINK>
</P>
</TD>
<TD>
<P>One patient on rhGH developed BIH. There were 22 episodes of acute rejection in 10 treated patients and 9 episodes in 7 control patients.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fine-1994-_x0028_preD_x0029_" TYPE="STUDY">Fine 1994 (preD)</LINK>
</P>
</TD>
<TD>
<P>Asthma/wheezing was reported in 8/55 children in the rhGH group and 0/27 children in the control group (RD 0.15, 95% CI 0.01 to 0.26). There were 3 episodes of acute rejection in control patients and none in rhGH treated children.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fine-2002-_x0028_TP_x0029_" TYPE="STUDY">Fine 2002 (TP)</LINK>
</P>
</TD>
<TD>
<P>During 1 year study, 3 control and 0 rhGH treated patients had rejection episodes. No graft loss in 1 year study. Other reported adverse effects: PTLD (1 control); Hodgkin's Lymphoma (1 treated); BIH (1 control); headache with normal CSF pressure (1 treated); DM (1 in each group); infection (3 treated, 2 control); TIA (1 treated), genu valgum (1 treated).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Callis-1996-_x0028_preD_x0029_" TYPE="STUDY">Callis 1996 (preD)</LINK>
</P>
</TD>
<TD>
<P>Kidney function fell in 9/21 and 11/23 respectively of the treatment groups</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hertel 2002 (preD/Dial)</LINK>
</P>
</TD>
<TD>
<P>14 IU group: DM (1); hypertension (1); injection pain (1). 28 IU group: injection pain (2)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1991 (preD/Dial)</LINK>
</P>
</TD>
<TD>
<P>Reported 'no adverse effects.'</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Hokken-K 1994 (preD/Dial)</LINK>
</P>
</TD>
<TD>
<P>Acute rejection and deterioration of kidney function reported - group not specified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1994 (TP)</LINK>
</P>
</TD>
<TD>
<P>Reported 'no adverse effects.'</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TYPE="STUDY">Hokken-K 1996 (TP)</LINK>
</P>
</TD>
<TD>
<P>Reported 'no acute rejection or serious deterioration of kidney function during rhGH therapy.'</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ito-1997-_x0028_TP_x0029_" TYPE="STUDY">Ito 1997 (TP)</LINK>
</P>
</TD>
<TD>
<P>Episodes of rejection were reported in 5/13 children in the 1.0 IU group and 2/10 children in the 0.5 IU group (RD 0.18, 95% CI -0.21 to 0.51). Glucose intolerance in 2/13 in 1.0 IU group.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kitagawa-1997-_x0028_Dial_x0029_" TYPE="STUDY">Kitagawa 1997 (Dial)</LINK>; <LINK REF="STD-Kitagawa-1997-_x0028_preD_x0029_" TYPE="STUDY">Kitagawa 1997 (preD)</LINK>
</P>
</TD>
<TD>
<P>More patients in the 1.0 IU than in the 0.5 IU group showed signs of deterioration in kidney function. Glucose intolerance (2), granuloma formation at the exit site of the Tenckhoff catheter, lymph node swelling in the groin, claudication, and hypertension reported - group not specified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuizon-1998-_x0028_Dial_x0029_" TYPE="STUDY">Kuizon 1998 (Dial)</LINK>
</P>
</TD>
<TD>
<P>Not addressed</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maxwell-1998a-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998a (TP)</LINK>; <LINK REF="STD-Maxwell-1998b-_x0028_TP_x0029_" TYPE="STUDY">Maxwell 1998b (TP)</LINK>
</P>
</TD>
<TD>
<P>Eight presumed rejection episodes in 13 patients in the treatment group and in 9 patients in the control group. One patient on rhGH had raised fasting glucose. One patient in the control group developed worsening of a pre-existing idiopathic scoliosis.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Powell-1997-_x0028_preD_x0029_" TYPE="STUDY">Powell 1997 (preD)</LINK>
</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sanchez-2002-_x0028_TP_x0029_" TYPE="STUDY">Sanchez 2002 (TP)</LINK>
</P>
</TD>
<TD>
<P>Not addressed</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TYPE="STUDY">Santos 2010 (preD/Dial)</LINK>
</P>
</TD>
<TD>
<P>There were 29 adverse events: 9 in the rhGH group and 20 in the untreated group, none were considered related to rhGH therapy.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BIH - benign intracranial hypertension; DM - diabetes mellitus; PTLD - post-transplant lymphoproliferative disease; rhGH - recombinant human growth hormone; TIA - transient ischaemic attack:</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-01-01 12:57:27 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-01-01 12:57:27 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>28 IU/m²/wk versus placebo/no treatment</NAME>
<CONT_OUTCOME CHI2="13.072489383027772" CI_END="1.0739283667388384" CI_START="0.5589810349713965" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8164547008551175" ESTIMABLE="YES" I2="38.802780667112025" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-11-16 22:19:49 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10937981676385278" P_Q="0.9961016062330924" P_Z="5.129549122811732E-10" Q="2.387232623926557E-5" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.05199186819091858" TOTALS="YES" TOTAL_1="191" TOTAL_2="140" UNITS="" WEIGHT="100.00000000000003" Z="6.215089233269932">
<NAME>HSDS after 1 year of rhGH</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.141102677991084" CI_END="1.130889433120673" CI_START="0.5469272247250582" DF="5" EFFECT_SIZE="0.8389083289228655" ESTIMABLE="YES" I2="38.583258340210364" ID="CMP-001.01.01" MODIFIED="2011-11-16 22:19:41 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14862886671564002" P_Z="1.788672465611262E-8" STUDIES="6" TAU2="0.046364235615026506" TOTAL_1="146" TOTAL_2="101" WEIGHT="73.36450831268911" Z="5.631289447777373">
<NAME>Change in HSDS after 1 year of rhGH</NAME>
<CONT_DATA CI_END="0.8128230331559876" CI_START="-0.21282303315598766" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.0" MODIFIED="2011-06-18 23:38:06 +1000" MODIFIED_BY="[Empty name]" ORDER="12849" SD_1="1.11" SD_2="1.3" SE="0.2616492125371029" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="41" TOTAL_2="44" WEIGHT="14.32698451492389"/>
<CONT_DATA CI_END="1.5291316163579243" CI_START="0.6508683836420759" EFFECT_SIZE="1.09" ESTIMABLE="YES" MEAN_1="1.01" MEAN_2="-0.08" ORDER="12848" SD_1="0.94" SD_2="0.96" SE="0.2240508600268874" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="16.887223980524734"/>
<CONT_DATA CI_END="2.0135652859846584" CI_START="-0.8135652859846584" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.1" ORDER="12850" SD_1="1.35" SD_2="0.44" SE="0.7212200311509196" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_" TOTAL_1="4" TOTAL_2="3" WEIGHT="3.0161948613641334"/>
<CONT_DATA CI_END="1.872330035866737" CI_START="-0.07233003586673703" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.3" ORDER="12851" SD_1="1.0" SD_2="0.9" SE="0.4960958688712406" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="6" WEIGHT="5.7889944669672495"/>
<CONT_DATA CI_END="1.038132839520016" CI_START="0.5618671604799841" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.0" ORDER="12852" SD_1="0.5" SD_2="0.3" SE="0.12149857925879118" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_" TOTAL_1="30" TOTAL_2="14" WEIGHT="25.851969430784262"/>
<CONT_DATA CI_END="2.327639405606642" CI_START="0.672360594393358" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="-0.1" MODIFIED="2011-07-28 17:26:56 +1000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="0.79" SD_2="0.79" SE="0.42227276222163057" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="7" TOTAL_2="7" WEIGHT="7.493141058124829"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.514400775652255" CI_END="1.524221012342125" CI_START="0.15730112570684984" DF="2" EFFECT_SIZE="0.8407610690244874" ESTIMABLE="YES" I2="55.697331730343905" ID="CMP-001.01.02" MODIFIED="2011-11-16 22:19:49 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10464316065307011" P_Z="0.015906328204845947" STUDIES="3" TAU2="0.20347067080237846" TOTAL_1="45" TOTAL_2="39" WEIGHT="26.63549168731091" Z="2.4110577818099683">
<NAME>HSDS after 1 year of rhGH</NAME>
<CONT_DATA CI_END="0.9102488627453768" CI_START="-0.09024886274537647" EFFECT_SIZE="0.41000000000000014" ESTIMABLE="YES" MEAN_1="-2.58" MEAN_2="-2.99" ORDER="12853" SD_1="1.04" SD_2="0.8" SE="0.2552337015839453" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_" TOTAL_1="30" TOTAL_2="22" WEIGHT="14.732574683443021"/>
<CONT_DATA CI_END="1.6873348140371438" CI_START="-0.04733481403714368" EFFECT_SIZE="0.8200000000000001" ESTIMABLE="YES" MEAN_1="-1.36" MEAN_2="-2.18" ORDER="12854" SD_1="0.59" SD_2="1.05" SE="0.44252589378099294" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_" TOTAL_1="6" TOTAL_2="8" WEIGHT="6.96355940389651"/>
<CONT_DATA CI_END="2.7388344915835416" CI_START="0.6011655084164587" EFFECT_SIZE="1.6700000000000002" ESTIMABLE="YES" MEAN_1="-1.14" MEAN_2="-2.81" MODIFIED="2011-07-28 17:35:50 +1000" MODIFIED_BY="[Empty name]" ORDER="12855" SD_1="1.09" SD_2="1.22" SE="0.5453337408311436" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.939357599971381"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.171963077566794" CI_END="1.1010232451338602" CI_START="0.5667766624538637" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.833899953793862" ESTIMABLE="YES" I2="43.550516211381975" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-11-16 22:20:55 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.07739195082312433" P_Q="0.3639086676475317" P_Z="9.441587892703417E-10" Q="0.8243595779298026" RANDOM="YES" SCALE="4.0" SORT_BY="WEIGHT" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.06236522033674913" TOTALS="YES" TOTAL_1="191" TOTAL_2="140" UNITS="" WEIGHT="100.00000000000001" Z="6.118574939484703">
<NAME>HSDS after 1 year according to treatment status</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.4481379848532865" CI_END="1.1648441232024749" CI_START="0.6899631416729516" DF="3" EFFECT_SIZE="0.9274036324377133" ESTIMABLE="YES" I2="12.996521218751463" ID="CMP-001.02.01" MODIFIED="2011-07-28 17:01:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3275511119986617" P_Z="1.9286445415922118E-14" STUDIES="4" TAU2="0.009512168401343448" TOTAL_1="98" TOTAL_2="56" WEIGHT="55.49707135351218" Z="7.655298019537704">
<NAME>Predialysis and dialysis patients</NAME>
<CONT_DATA CI_END="1.6873348140371438" CI_START="-0.04733481403714368" EFFECT_SIZE="0.8200000000000001" ESTIMABLE="YES" MEAN_1="-1.36" MEAN_2="-2.18" MODIFIED="2011-06-02 14:05:57 +1000" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="0.59" SD_2="1.05" SE="0.44252589378099294" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_" TOTAL_1="6" TOTAL_2="8" WEIGHT="7.194167342319988"/>
<CONT_DATA CI_END="2.327639405606642" CI_START="0.672360594393358" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="-0.1" MODIFIED="2011-07-28 17:01:17 +1000" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="0.79" SD_2="0.79" SE="0.42227276222163057" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="7" TOTAL_2="7" WEIGHT="7.717705829745347"/>
<CONT_DATA CI_END="1.5291316163579243" CI_START="0.6508683836420759" EFFECT_SIZE="1.09" ESTIMABLE="YES" MEAN_1="1.01" MEAN_2="-0.08" MODIFIED="2011-06-02 14:04:56 +1000" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="0.94" SD_2="0.96" SE="0.2240508600268874" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="16.501665642481232"/>
<CONT_DATA CI_END="1.038132839520016" CI_START="0.5618671604799841" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.0" MODIFIED="2011-06-02 14:05:22 +1000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="0.5" SD_2="0.3" SE="0.12149857925879118" STUDY_ID="STD-Powell-1997-_x0028_preD_x0029_" TOTAL_1="30" TOTAL_2="14" WEIGHT="24.083532538965613"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.647915356778537" CI_END="1.1542801537194565" CI_START="0.21152416742587365" DF="4" EFFECT_SIZE="0.6829021605726651" ESTIMABLE="YES" I2="47.69816592629126" ID="CMP-001.02.02" MODIFIED="2011-07-24 14:37:09 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10536110256881948" P_Z="0.004518855314493444" STUDIES="5" TAU2="0.12871570701847698" TOTAL_1="93" TOTAL_2="84" WEIGHT="44.50292864648783" Z="2.8394699352674335">
<NAME>Transplant patients</NAME>
<CONT_DATA CI_END="2.0135652859846584" CI_START="-0.8135652859846584" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.1" MODIFIED="2011-06-02 14:05:06 +1000" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="1.35" SD_2="0.44" SE="0.7212200311509196" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_" TOTAL_1="4" TOTAL_2="3" WEIGHT="3.1887013241739415"/>
<CONT_DATA CI_END="1.872330035866737" CI_START="-0.07233003586673703" EFFECT_SIZE="0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.3" MODIFIED="2011-06-02 14:05:15 +1000" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="1.0" SD_2="0.9" SE="0.4960958688712406" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="6" WEIGHT="6.021511012634246"/>
<CONT_DATA CI_END="2.623935882899785" CI_START="0.7760641171002144" EFFECT_SIZE="1.6999999999999997" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-2.8" MODIFIED="2011-07-24 14:37:09 +1000" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="1.0" SD_2="1.0" SE="0.4714045207910317" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.526969743457314"/>
<CONT_DATA CI_END="0.8128230331559876" CI_START="-0.21282303315598766" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.0" MODIFIED="2011-06-02 14:04:46 +1000" MODIFIED_BY="[Empty name]" ORDER="66" SD_1="1.11" SD_2="1.3" SE="0.2616492125371029" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="41" TOTAL_2="44" WEIGHT="14.198250266500196"/>
<CONT_DATA CI_END="0.9102488627453768" CI_START="-0.09024886274537647" EFFECT_SIZE="0.41000000000000014" ESTIMABLE="YES" MEAN_1="-2.58" MEAN_2="-2.99" MODIFIED="2011-06-02 14:05:48 +1000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="1.04" SD_2="0.8" SE="0.2552337015839453" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_" TOTAL_1="30" TOTAL_2="22" WEIGHT="14.567496299722135"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2011-07-24 15:23:53 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="66" TOTAL_2="59" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in height SDS according to pubertal status</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2011-07-24 14:50:42 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Prepubertal</NAME>
<CONT_DATA CI_END="0.6545054130814074" CI_START="0.3454945869185926" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.1" MODIFIED="2011-05-19 16:51:19 +1000" MODIFIED_BY="[Empty name]" ORDER="860" SD_1="0.3" SD_2="0.3" SE="0.07883074092183653" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" MODIFIED="2011-07-21 11:50:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Entering puberty</NAME>
<CONT_DATA CI_END="1.157748967767713" CI_START="0.24225103223228678" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.1" MODIFIED="2011-05-19 16:52:15 +1000" MODIFIED_BY="[Empty name]" ORDER="861" SD_1="0.6" SD_2="0.4" SE="0.2335496832484569" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.03" MODIFIED="2011-07-24 14:50:48 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Pubertal</NAME>
<CONT_DATA CI_END="0.8940571696935675" CI_START="0.3059428303064325" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.1" MODIFIED="2011-05-19 16:53:06 +1000" MODIFIED_BY="[Empty name]" ORDER="862" SD_1="0.5" SD_2="0.5" SE="0.15003192508283464" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="29" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.024019888467651046" CI_END="3.482133018424153" CI_START="2.217513488883899" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.849823253654026" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-11-16 22:21:16 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8768343332600669" P_Q="1.0" P_Z="1.0138917560318976E-18" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="8.833567423234792">
<NAME>Height velocity (cm/6 mo) after 6 months of rhGH</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.024019888467651046" CI_END="3.482133018424153" CI_START="2.217513488883899" DF="1" EFFECT_SIZE="2.849823253654026" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.8768343332600669" P_Z="1.0138917560318976E-18" STUDIES="2" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="8.833567423234792">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="3.6926447198535817" CI_START="1.9073552801464189" EFFECT_SIZE="2.8000000000000003" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="0.9" ORDER="12856" SD_1="0.95" SD_2="0.87" SE="0.4554393483220351" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="8" TOTAL_2="8" WEIGHT="50.17674634597447"/>
<CONT_DATA CI_END="3.7958057505845044" CI_START="2.0041942494154954" EFFECT_SIZE="2.9" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="0.9" ORDER="12857" SD_1="0.89" SD_2="0.62" SE="0.4570521487387043" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TOTAL_1="6" TOTAL_2="5" WEIGHT="49.823253654025535"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.709483482074392" CI_END="4.43628141480204" CI_START="3.3204228714797974" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8783521431409187" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-07-24 14:47:20 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.45974221742402543" P_Q="0.9384926277720315" P_Z="2.8690552272676663E-42" Q="0.005954370664285305" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="126" UNITS="" WEIGHT="99.99999999999999" Z="13.624362273175265">
<NAME>Height velocity (cm/y) after 1 year of rhGH</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.7994432459166587" CI_END="5.58094798407183" CI_START="2.5685886391478547" DF="2" EFFECT_SIZE="4.0747683116098425" ESTIMABLE="YES" I2="47.36070864726189" ID="CMP-001.05.01" NO="1" P_CHI2="0.14961037798086074" P_Z="1.1427675375396618E-7" STUDIES="3" TAU2="0.8615105159453645" TOTAL_1="54" TOTAL_2="53" WEIGHT="41.165274934599324" Z="5.302421272918841">
<NAME>Change in height velocity (cm/y) after 1 year of rhGH</NAME>
<CONT_DATA CI_END="4.209792849671357" CI_START="2.1902071503286438" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="0.4" ORDER="12858" SD_1="2.29" SD_2="2.46" SE="0.51520990060862" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="41" TOTAL_2="44" WEIGHT="30.527673776408335"/>
<CONT_DATA CI_END="7.538651467789714" CI_START="1.2613485322102842" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="1.2" ORDER="12859" SD_1="2.17" SD_2="2.04" SE="1.6013822154626296" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_" TOTAL_1="4" TOTAL_2="3" WEIGHT="3.1598910605569834"/>
<CONT_DATA CI_END="7.440303784714663" CI_START="3.359696215285338" EFFECT_SIZE="5.4" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="-1.2" ORDER="12860" SD_1="2.36" SD_2="1.67" SE="1.0409904471757228" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="6" WEIGHT="7.477710097634006"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.609370167566246" CI_END="4.736298103501994" CI_START="3.2815349967198517" DF="4" EFFECT_SIZE="4.008916550110923" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2011-05-19 16:37:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6251642819839486" P_Z="3.359979888681696E-27" STUDIES="5" TAU2="0.0" TOTAL_1="107" TOTAL_2="73" WEIGHT="58.83472506540066" Z="10.802215176633075">
<NAME>Growth velocity (cm/y) after 1 year of rhGH</NAME>
<CONT_DATA CI_END="5.477886963206732" CI_START="2.9221130367932666" EFFECT_SIZE="4.199999999999999" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="6.5" ORDER="12861" SD_1="3.1" SD_2="2.6" SE="0.651995125056655" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="19.062217268298394"/>
<CONT_DATA CI_END="5.5510448699554065" CI_START="3.1689551300445924" EFFECT_SIZE="4.359999999999999" ESTIMABLE="YES" MEAN_1="8.59" MEAN_2="4.23" ORDER="12862" SD_1="2.46" SD_2="1.92" SE="0.6076871204523232" STUDY_ID="STD-Fine-2002-_x0028_TP_x0029_" TOTAL_1="30" TOTAL_2="22" WEIGHT="21.943305456918374"/>
<CONT_DATA CI_END="5.247284065876773" CI_START="0.15271593412322648" EFFECT_SIZE="2.6999999999999997" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="3.6" ORDER="12864" SD_1="2.94" SD_2="1.41" SE="1.2996586090200763" STUDY_ID="STD-Kuizon-1998-_x0028_Dial_x0029_" TOTAL_1="6" TOTAL_2="8" WEIGHT="4.797373551476793"/>
<CONT_DATA CI_END="4.965177025779791" CI_START="1.4348229742202085" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="4.8" ORDER="12865" SD_1="2.1" SD_2="1.7" SE="0.9006170724070864" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="9" WEIGHT="9.99037434201638"/>
<CONT_DATA CI_END="8.199178622395475" CI_START="1.8008213776045254" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="14.5" MEAN_2="9.5" MODIFIED="2011-02-16 08:31:36 +1100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="3.2" SD_2="2.9" SE="1.6322639842518472" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="7" TOTAL_2="7" WEIGHT="3.041454446690718"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-11-02 21:36:38 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="66" TOTAL_2="59" UNITS="cm/yr" WEIGHT="0.0" Z="0.0">
<NAME>Height velocity (cm/y) according to pubertal status</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2011-05-19 16:59:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Prepubertal</NAME>
<CONT_DATA CI_END="4.224028869767507" CI_START="2.5759711302324937" EFFECT_SIZE="3.4000000000000004" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="0.3" MODIFIED="2011-05-19 16:59:24 +1000" MODIFIED_BY="[Empty name]" ORDER="863" SD_1="1.6" SD_2="1.6" SE="0.42043061824979494" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2011-05-19 16:59:49 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Entering puberty</NAME>
<CONT_DATA CI_END="6.530009653600882" CI_START="2.0699903463991194" EFFECT_SIZE="4.300000000000001" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="0.6" MODIFIED="2011-05-19 16:59:49 +1000" MODIFIED_BY="[Empty name]" ORDER="864" SD_1="3.0" SD_2="1.8" SE="1.1377809343390557" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.03" MODIFIED="2011-05-19 17:00:16 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Pubertal</NAME>
<CONT_DATA CI_END="4.85788856495088" CI_START="2.3421114350491195" EFFECT_SIZE="3.5999999999999996" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="0.7" MODIFIED="2011-05-19 17:00:16 +1000" MODIFIED_BY="[Empty name]" ORDER="865" SD_1="2.2" SD_2="2.1" SE="0.6417916731495805" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="29" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1974971829213417" CI_END="8.77648832000981" CI_START="5.884841107395568" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="7.330664713702689" ESTIMABLE="YES" I2="0.0" I2_Q="3.0264395208652735" ID="CMP-001.07" MODIFIED="2011-07-24 15:23:36 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7536047157950189" P_Q="0.30987521252601014" P_Z="2.859784602896051E-23" Q="1.0312089141196012" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="22" UNITS="" WEIGHT="200.0" Z="9.93747699160467">
<NAME>Change in height velocity SDS</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.013186266174123138" CI_END="9.507397901109401" CI_START="6.093826168990986" DF="1" EFFECT_SIZE="7.800612035050194" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.9085787077136466" P_Z="3.314454947985274E-19" STUDIES="2" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.00000000000001" Z="8.957725131254227">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="10.12118032757052" CI_START="5.278819672429478" EFFECT_SIZE="7.699999999999999" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="2.4" ORDER="12866" SD_1="2.09" SD_2="2.8" SE="1.2353187847677214" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="8" TOTAL_2="8" WEIGHT="49.69398247490284"/>
<CONT_DATA CI_END="10.306406926185309" CI_START="5.493593073814692" EFFECT_SIZE="7.9" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="2.9" ORDER="12867" SD_1="2.54" SD_2="1.47" SE="1.2277811965764367" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TOTAL_1="6" TOTAL_2="5" WEIGHT="50.306017525097175"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15310200262761806" CI_END="8.857224650115795" CI_START="3.4159530459169782" DF="1" EFFECT_SIZE="6.136588848016387" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.6955885959329026" P_Z="9.831836453580244E-6" STUDIES="2" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="100.0" Z="4.420839099728494">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="9.691635510971356" CI_START="1.308364489028647" EFFECT_SIZE="5.500000000000001" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="2.8" ORDER="12868" SD_1="3.38" SD_2="2.27" SE="2.1386288442208325" STUDY_ID="STD-Maxwell-1998a-_x0028_TP_x0029_" TOTAL_1="4" TOTAL_2="3" WEIGHT="42.128286543964805"/>
<CONT_DATA CI_END="10.17632713856873" CI_START="3.0236728614312693" EFFECT_SIZE="6.6" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="-0.5" ORDER="12869" SD_1="4.39" SD_2="2.67" SE="1.8246902324626075" STUDY_ID="STD-Maxwell-1998b-_x0028_TP_x0029_" TOTAL_1="9" TOTAL_2="6" WEIGHT="57.87171345603519"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-01-01 12:57:27 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="330" TOTAL_2="162" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Growth after 2 years of rhGH</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2011-06-02 17:30:49 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Change in height SDS after 1 year of rhGH</NAME>
<CONT_DATA CI_END="1.5291316163579243" CI_START="0.6508683836420759" EFFECT_SIZE="1.09" ESTIMABLE="YES" MEAN_1="1.01" MEAN_2="-0.08" MODIFIED="2011-06-02 17:16:21 +1000" MODIFIED_BY="[Empty name]" ORDER="186" SD_1="0.94" SD_2="0.96" SE="0.2240508600268874" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" MODIFIED="2011-06-02 17:31:05 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Change in height SDS between 1 and 2 years of rhGH</NAME>
<CONT_DATA CI_END="0.8446143145922562" CI_START="-0.10461431459225623" EFFECT_SIZE="0.37" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.01" ORDER="12870" SD_1="1.09" SD_2="1.0" SE="0.24215461015404025" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.03" MODIFIED="2011-07-13 11:33:34 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Height SDS after 2 years of rhGH</NAME>
<CONT_DATA CI_END="1.8578644705116867" CI_START="0.8621355294883136" EFFECT_SIZE="1.36" ESTIMABLE="YES" MEAN_1="-1.55" MEAN_2="-2.91" MODIFIED="2011-07-13 11:32:40 +1000" MODIFIED_BY="[Empty name]" ORDER="76" SD_1="1.16" SD_2="1.04" SE="0.25401715257972995" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.04" MODIFIED="2012-01-01 12:57:27 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Growth velocity (cm/y) after 1 year of rhGH</NAME>
<CONT_DATA CI_END="5.477886963206732" CI_START="2.9221130367932666" EFFECT_SIZE="4.199999999999999" ESTIMABLE="YES" MEAN_1="10.7" MEAN_2="6.5" MODIFIED="2011-06-02 17:10:55 +1000" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="3.1" SD_2="2.6" SE="0.651995125056655" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.05" MODIFIED="2012-01-01 12:57:21 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Growth velocity (cm/y) in second year of rhGH therapy</NAME>
<CONT_DATA CI_END="3.206439421398862" CI_START="1.3935605786011374" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="5.5" ORDER="12873" SD_1="2.1" SD_2="1.9" SE="0.46247759068469674" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.06" MODIFIED="2012-01-01 12:57:15 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Change in growth velocity (cm/y) between 1 and 2 years of rhGH</NAME>
<CONT_DATA CI_END="-0.761242053228683" CI_START="-3.038757946771317" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-1.0" ORDER="12872" SD_1="2.74" SD_2="2.33" SE="0.5810096286226146" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8047948590173601" CI_END="0.30565070332954203" CI_START="-0.25055012579703007" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.02755028876625597" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2011-07-28 16:58:53 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9919444881854407" P_Q="0.8490794962598968" P_Z="0.8460461052628484" Q="0.3272049783024421" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="128" UNITS="" WEIGHT="300.0" Z="0.19416574344319132">
<NAME>Change in bone age</NAME>
<GROUP_LABEL_1>rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Placebo/no treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.00363976626634293" CI_END="1.4751193974807213" CI_START="-1.7723242086450977" DF="1" EFFECT_SIZE="-0.14860240558218818" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="0.9518924727160643" P_Z="0.8576431322876248" STUDIES="2" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.17937516291749783">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="2.129071063522415" CI_START="-2.5290710635224154" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.3" ORDER="12874" SD_1="2.13" SD_2="2.6" SE="1.1883233987429516" STUDY_ID="STD-Hokken_x002d_K-1991-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="8" TOTAL_2="8" WEIGHT="48.60240558218818"/>
<CONT_DATA CI_END="2.1648540764443402" CI_START="-2.3648540764443404" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.3" ORDER="12875" SD_1="1.57" SD_2="2.15" SE="1.1555590277725611" STUDY_ID="STD-Hokken_x002d_K-1996-_x0028_TP_x0029_" TOTAL_1="6" TOTAL_2="5" WEIGHT="51.3975944178118"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4739501144485752" CI_END="0.3053213185294643" CI_START="-0.27128259656610854" DF="3" EFFECT_SIZE="0.017019360981677882" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2011-07-28 16:58:53 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9245760695621685" P_Z="0.9078881123048068" STUDIES="4" TAU2="0.0" TOTAL_1="114" TOTAL_2="88" WEIGHT="100.0" Z="0.11570276819381599">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="1.172421258390874" CI_START="-1.3724212583908737" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.0" ORDER="12877" SD_1="3.15" SD_2="2.81" SE="0.649206448908026" STUDY_ID="STD-Broyer-1996-_x0028_TP_x0029_" TOTAL_1="41" TOTAL_2="44" WEIGHT="5.133733853212019"/>
<CONT_DATA CI_END="1.6496073456108131" CI_START="-1.049607345610813" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.8" ORDER="12876" SD_1="2.55" SD_2="3.1" SE="0.6885878292949991" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="4.563313603753606"/>
<CONT_DATA CI_END="3.3219867266875838" CI_START="-1.9219867266875836" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="0.7" ORDER="12878" SD_1="3.5" SD_2="2.6" SE="1.3377729118338297" STUDY_ID="STD-Sanchez-2002-_x0028_TP_x0029_" TOTAL_1="11" TOTAL_2="10" WEIGHT="1.209022003375582"/>
<CONT_DATA CI_END="0.30543832660573966" CI_START="-0.30543832660573966" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.98" MEAN_2="0.98" MODIFIED="2011-07-28 16:58:53 +1000" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="0.26" SD_2="0.32" SE="0.15583874449479593" STUDY_ID="STD-Santos-2010-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="7" TOTAL_2="7" WEIGHT="89.09393053965879"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.787329312274878" CI_START="-0.9873293122748781" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" NO="3" P_CHI2="1.0" P_Z="0.5720029079991307" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="27" WEIGHT="100.0" Z="0.5651041802976673">
<NAME>1 to 2 years</NAME>
<CONT_DATA CI_END="1.787329312274878" CI_START="-0.9873293122748781" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.8" ORDER="12879" SD_1="2.71" SD_2="3.15" SE="0.7078340843086682" STUDY_ID="STD-Fine-1994-_x0028_preD_x0029_" TOTAL_1="55" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-11-16 22:22:43 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>28 IU/m²/wk versus 14 IU/m²/wk</NAME>
<CONT_OUTCOME CHI2="0.6444110807285173" CI_END="0.4144634355912663" CI_START="-0.043018656398460725" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1857223895964028" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-11-16 22:22:17 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9987273570759923" P_Q="0.972987282453243" P_Z="0.11152873451008227" Q="0.054768581781114024" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="151" UNITS="" WEIGHT="300.0" Z="1.5913593170324138">
<NAME>Final or change in HSDS</NAME>
<GROUP_LABEL_1>28 IU rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>14 IU rhGH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 14 IU rhGH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 28 IU rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.566581328061178" CI_END="0.4824687360149481" CI_START="-0.08769488993439481" DF="3" EFFECT_SIZE="0.19738692304027664" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2011-11-16 22:22:17 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9040383489535344" P_Z="0.1747642252164992" STUDIES="4" TAU2="0.0" TOTAL_1="74" TOTAL_2="71" WEIGHT="99.99999999999999" Z="1.3570534582382983">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="0.9666574309407693" CI_START="-0.36665743094076875" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.2" MODIFIED="2011-05-19 16:32:57 +1000" MODIFIED_BY="[Empty name]" ORDER="858" SD_1="0.9" SD_2="1.3" SE="0.34013759242479846" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_" TOTAL_1="23" TOTAL_2="21" WEIGHT="18.286625687285966"/>
<CONT_DATA CI_END="0.48570613609276286" CI_START="-0.2857061360927629" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.4" ORDER="12880" SD_1="0.5" SD_2="0.4" SE="0.19679246105293957" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="11" TOTAL_2="10" WEIGHT="54.629336781369055"/>
<CONT_DATA CI_END="1.505866047031136" CI_START="-0.7058660470311361" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="-0.1" ORDER="12881" SD_1="1.95" SD_2="1.05" SE="0.5642277387513579" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="6.645596603014761"/>
<CONT_DATA CI_END="0.9305878954804474" CI_START="-0.3305878954804475" EFFECT_SIZE="0.3" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.3" ORDER="12882" SD_1="0.85" SD_2="1.31" SE="0.32173443004792146" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="20.43844092833021"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.065607619768057E-32" CI_END="0.7269867195863735" CI_START="-0.3269867195863736" DF="1" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.9999999999999999" P_Z="0.45697443699065843" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.7438380937107522">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="1.305866047031136" CI_START="-0.9058660470311362" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.0" ORDER="12883" SD_1="1.95" SD_2="1.05" SE="0.5642277387513579" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="22.7088056301192"/>
<CONT_DATA CI_END="0.7994247373055949" CI_START="-0.39942473730559486" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.2" ORDER="12884" SD_1="0.8" SD_2="1.25" SE="0.3058345673868401" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="77.2911943698808"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.02306117088622527" CI_END="0.6833429724223565" CI_START="-0.43346667309347" DF="1" EFFECT_SIZE="0.12493814966444325" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="0.8792981214824259" P_Z="0.6610060140596045" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.43852463957594584">
<NAME>6 months to 1 year</NAME>
<CONT_DATA CI_END="1.3181937152278003" CI_START="-0.9181937152278004" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="-0.1" ORDER="12885" SD_1="2.0" SD_2="1.0" SE="0.570517480957798" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="24.93814966444325"/>
<CONT_DATA CI_END="0.7445246438041669" CI_START="-0.544524643804167" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.1" ORDER="12886" SD_1="0.85" SD_2="1.35" SE="0.32884514658845526" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="75.06185033555674"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.042864544925761" CI_END="1.5019807841424426" CI_START="0.4909620958095616" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9964714399760021" ESTIMABLE="YES" I2="41.87429432684737" I2_Q="80.83477117254725" ID="CMP-002.02" MODIFIED="2011-11-16 22:22:43 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09915808060063946" P_Q="0.005419340422944896" P_Z="1.1176231787873613E-4" Q="10.435565460795074" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.39893084070749996" TOTALS="SUB" TOTAL_1="157" TOTAL_2="153" UNITS="" WEIGHT="300.0" Z="3.8635252869483727">
<NAME>Final/change in height velocity (cm/time period)</NAME>
<GROUP_LABEL_1>28 IU rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>14 IU rhGH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 14 IU rhGH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 28 IU rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4458681722186624" CI_END="3.050547768214969" CI_START="0.8606736282745071" DF="1" EFFECT_SIZE="1.955610698244738" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.5043036781158692" P_Z="4.6422821655900674E-4" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="3.5005907110671886">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="4.437066986795856" CI_START="0.5629330132041435" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="2.0" ORDER="12887" SD_1="3.03" SD_2="2.49" SE="0.9883176436277369" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="31.951337280592284"/>
<CONT_DATA CI_END="3.0273313802418915" CI_START="0.3726686197581086" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="3.7" ORDER="12888" SD_1="2.51" SD_2="2.18" SE="0.6772223319977877" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="68.0486627194077"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.006757576257485232" CI_END="0.5853732293981276" CI_START="-1.6506652132533066" DF="1" EFFECT_SIZE="-0.5326459919275895" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="0.9344841125009666" P_Z="0.3504252573429122" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.933764769669863">
<NAME>6 months to 1 year</NAME>
<CONT_DATA CI_END="1.3567454637597836" CI_START="-2.5567454637597837" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.3" ORDER="12889" SD_1="2.99" SD_2="2.61" SE="0.9983578673865143" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="32.64599192758951"/>
<CONT_DATA CI_END="0.8622836610760887" CI_START="-1.8622836610760887" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.8" ORDER="12890" SD_1="2.62" SD_2="2.19" SE="0.6950554560296047" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="67.3540080724105"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1546733356545402" CI_END="1.8445870671512927" CI_START="0.5198101692445735" DF="3" EFFECT_SIZE="1.1821986181979331" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" MODIFIED="2011-05-19 16:35:06 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7638948017350324" P_Z="4.686764418143554E-4" STUDIES="4" TAU2="0.0" TOTAL_1="77" TOTAL_2="73" WEIGHT="100.0" Z="3.498048188947385">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="2.026277356482673" CI_START="-0.4262773564826732" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.3" MODIFIED="2011-05-19 16:35:06 +1000" MODIFIED_BY="[Empty name]" ORDER="859" SD_1="2.15" SD_2="2.0" SE="0.6256632091994507" STUDY_ID="STD-Callis-1996-_x0028_preD_x0029_" TOTAL_1="23" TOTAL_2="21" WEIGHT="29.1775003441552"/>
<CONT_DATA CI_END="3.202547096137822" CI_START="-1.2025470961378222" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="2.6" ORDER="12891" SD_1="1.6" SD_2="3.6" SE="1.1237691679598363" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="14" TOTAL_2="12" WEIGHT="9.044302796610076"/>
<CONT_DATA CI_END="3.5202200029006843" CI_START="0.279779997099316" EFFECT_SIZE="1.9000000000000001" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="1.7" ORDER="12892" SD_1="2.31" SD_2="2.36" SE="0.8266580486584308" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="16.71388930968202"/>
<CONT_DATA CI_END="2.1867256078880044" CI_START="0.21327439211199506" EFFECT_SIZE="1.1999999999999997" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="2.9" ORDER="12893" SD_1="1.93" SD_2="1.55" SE="0.5034406834366194" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="45.06430754955271"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.492179623307145" CI_END="1.8646178504001467" CI_START="0.2807130066735084" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0726654285368276" ESTIMABLE="YES" I2="48.118093625823" I2_Q="75.4142188751787" ID="CMP-002.03" MODIFIED="2011-07-28 14:24:54 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06098677842653499" P_Q="0.01712205756917118" P_Z="0.007938208420257295" Q="8.134783230380428" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.9707386556130335" TOTALS="SUB" TOTAL_1="146" TOTAL_2="143" UNITS="" WEIGHT="300.0" Z="2.6546867581348845">
<NAME>Final/change in height velocity SDS</NAME>
<GROUP_LABEL_1>28 IU rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>14 IU rhGH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 14 IU rhGH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 28 IU rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.413675075792853" CI_END="2.9289192623981366" CI_START="0.029233382948418818" DF="2" EFFECT_SIZE="1.4790763226732777" ESTIMABLE="YES" I2="41.41211581083228" ID="CMP-002.03.01" NO="1" P_CHI2="0.18143894538362315" P_Z="0.04555611851951028" STUDIES="3" TAU2="0.7037856492884716" TOTAL_1="54" TOTAL_2="52" WEIGHT="100.0" Z="1.999483008397936">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="3.0980624981496643" CI_START="-1.4980624981496646" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.0" ORDER="12894" SD_1="2.4" SD_2="3.4" SE="1.1725024114098463" STUDY_ID="STD-Hertel-2002-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="14" TOTAL_2="12" WEIGHT="26.326054076393476"/>
<CONT_DATA CI_END="5.844749011757779" CI_START="0.9552509882422218" EFFECT_SIZE="3.4000000000000004" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="2.8" ORDER="12895" SD_1="4.1" SD_2="2.72" SE="1.2473438446020675" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="24.216095069986856"/>
<CONT_DATA CI_END="2.1436277858907617" CI_START="-0.3436277858907626" EFFECT_SIZE="0.8999999999999995" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.2" ORDER="12896" SD_1="2.61" SD_2="1.73" SE="0.6345156317668791" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="49.457850853619654"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.925484867199557" CI_END="3.309966106306521" CI_START="0.8086204585860022" DF="2" EFFECT_SIZE="2.0592932824462618" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" MODIFIED="2011-05-04 09:19:43 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38184434502948406" P_Z="0.0012501876486153642" STUDIES="3" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="100.00000000000001" Z="3.2271754772300945">
<NAME>Baseline to 6 months</NAME>
<CONT_DATA CI_END="4.290727022742985" CI_START="-2.090727022742986" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="8.1" MODIFIED="2011-05-04 09:19:43 +1000" MODIFIED_BY="[Empty name]" ORDER="12897" SD_1="3.9" SD_2="3.9" SE="1.6279518643766075" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_preD_x002f_Dial_x0029_" TOTAL_1="12" TOTAL_2="11" WEIGHT="15.36413537892296"/>
<CONT_DATA CI_END="6.16567812697418" CI_START="1.0343218730258195" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="2.9" ORDER="12898" SD_1="4.34" SD_2="2.79" SE="1.3090435065194679" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="23.7620049852526"/>
<CONT_DATA CI_END="3.3029807012574226" CI_START="0.09701929874257798" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="5.0" ORDER="12899" SD_1="3.21" SD_2="2.43" SE="0.8178623249720552" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="60.87385963582445"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.12624249892560246" CI_END="0.7978669466116861" CI_START="-2.0907573683558036" DF="1" EFFECT_SIZE="-0.6464452108720586" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.03" NO="3" P_CHI2="0.7223602802014191" P_Z="0.3803559520539783" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.8772406468522684">
<NAME>6 months to 1 year</NAME>
<CONT_DATA CI_END="2.6549927462111382" CI_START="-3.0549927462111386" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.1" ORDER="12900" SD_1="4.86" SD_2="3.05" SE="1.456655718539196" STUDY_ID="STD-Kitagawa-1997-_x0028_Dial_x0029_" TOTAL_1="15" TOTAL_2="17" WEIGHT="25.592464854656907"/>
<CONT_DATA CI_END="0.87437452540712" CI_START="-2.47437452540712" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-0.8" ORDER="12901" SD_1="3.4" SD_2="2.48" SE="0.8542884147945434" STUDY_ID="STD-Kitagawa-1997-_x0028_preD_x0029_" TOTAL_1="25" TOTAL_2="23" WEIGHT="74.40753514534309"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-11-16 22:23:18 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>56 IU/m²/wk versus 28 IU/m²/wk</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-11-16 22:23:18 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in HSDS</NAME>
<GROUP_LABEL_1>56 IU rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>28 IU rhGH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 28 IU rhGH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 56 IU rhGH</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6044568682680633" CI_START="-1.0044568682680632" EFFECT_SIZE="0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.7" ORDER="12902" SD_1="1.11" SD_2="1.55" SE="0.6655514481681565" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-10-02 17:24:17 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="7" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in height velocity (cm/y)</NAME>
<GROUP_LABEL_1>56 IU rhGH</GROUP_LABEL_1>
<GROUP_LABEL_2>28 IU rhGH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 28 IU rhGH</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 56 IU rhGH</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Baseline to 1 year</NAME>
<CONT_DATA CI_END="3.427557520035403" CI_START="-1.2275575200354036" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="6.7" ORDER="12903" SD_1="2.1" SD_2="2.65" SE="1.1875511684882374" STUDY_ID="STD-Hokken_x002d_K-1994-_x0028_TP_x0029_" TOTAL_1="7" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-01-01 17:11:54 +1100" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="flowchart2.PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-01 17:11:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart comparing study selection, interventions investigated, numbers of children and outcomes reported between initial review and latest update</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-01-01 17:11:54 +1100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-01-01 17:11:54 +1100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-12-29 14:35:56 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-11-02 21:11:59 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2008-10-02 17:27:52 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-02 21:11:59 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>GROWTH HORMONE</LI>
<LI>SOMATOTROPIN</LI>
<LI>(growth next hormone) or (rhGh) or (hGH)</LI>
<LI>somatotropin</LI>
<LI>(#1 or #2 or #3 or #4)</LI>
<LI>KIDNEY FAILURE CHRONIC</LI>
<LI>((chronic next kidney next failure) or (chronic next renal next failure))</LI>
<LI>DIALYSIS EXTRACORPOREAL</LI>
<LI>dialysis</LI>
<LI>KIDNEY TRANSPLANTATION</LI>
<LI>((kidney next transplant) or (renal next transplant))</LI>
<LI>((end next stage next renal next disease) or (end next stage next renal next failure) or (end next stage next kidney next disease) or (end next stage next kidney next failure))</LI>
<LI>(#6 or #7 or #8 or #9 or #10 or #11 or #12)</LI>
<LI>(#5 and #13)</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>exp somatotropin/ or "growth hormone".mp.</LI>
<LI>exp kidney failure, chronic/ or "chronic kidney failure".mp.</LI>
<LI>exp dialysis/ or exp peritoneal dialysis/ or exp peritoneal dialysis, continuous ambulatory/ or "dialysis".mp.</LI>
<LI>exp hemodialysis/ or exp hemodialysis units, hospital/ or exp hemodialysis, home/ or "hemodialysis".mp.</LI>
<LI>exp kidney transplantation/ or "kidney transplantation".mp.</LI>
<LI>"END-STAGE RENAL DISEASE".mp.</LI>
<LI>or/2-6</LI>
<LI>1 and 7</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>exp growth hormone/ or "growth hormone".mp.</LI>
<LI>exp chronic kidney failure/ or "chronic kidney failure".mp.</LI>
<LI>exp continuous ambulatory peritoneal dialysis/ or exp dialysis/ or exp home dialysis/ or exp peritoneal dialysis/ or "dialysis".mp.</LI>
<LI>exp hemodialysis/ or "hemodialysis".mp.</LI>
<LI>exp kidney transplantation/ or "kidney transplantation".mp.</LI>
<LI>"END-STAGE RENAL DISEASE".mp.</LI>
<LI>1 or 2 or 3 or 4 or 5 or 6</LI>
</OL>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-12-29 14:35:56 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2011-12-29 14:35:40 +1100" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-29 14:35:56 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>:<I> </I>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>



<EXTENSION ID="AFF_16110_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="16110"><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98453430</PHONE_1><FAX_1>+61 2 98453432</FAX_1></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_9199_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="9199"><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="4552"><ADDRESS><DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>